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Oesophageal squamous cell carcinoma (OSCC) is a major cancer in South Africa, affecting 
mainly black males. Several risk factors for OSCC have been reported but this study 
focuses on the role of human papilloma virus (HPV) in the development of OSCC. HPV is 
a well-known risk factor for cervical cancer resulting in its classification into low- and 
high-risk HPV types. The role of the different HPV types in OSCC development is not 
known, but in cervical cancer the critical HPV transforming gene has been shown to be E6. 
In this project, the effects ofHPVl1 E6, a low-risk type, and HPV18 E6, a high-risk type, 
were investigated by transfecting HPV-negative cell lines (EPC2-hTERT, MCF12A and 
Rat 1) with HPV 11 and HPV 18 E6. It was observed that the HPV 18 E6 protein caused a 
decrease in p53 protein levels but the HPVll E6 protein did not. The HPVll E6 gene, 
when transcribed at higher levels, caused a decrease in cell growth, an increase in the 
proportion of cells in G2 and a 4-fold increase in the percentage of cells with DNA content 
greater than G2. HPV 18 E6 did not appear to affect the growth rate or the cell cycle 
profile of the cells. In addition, an HPV-positive cell line (HeLa) was used to determine 
the effects of down regulating HPV E6 using peptide nucleic acids (PNAs). PNAs 
targeting the HPV18 E6 gene (PNA1s) were used to determine the effects of down 
regulating HPV18 E6 expression. Treatment with PNAls caused a 15-35% decrease in 
HPV18 E6 mRNA levels as well as a decrease in the growth rate of the He La cells. 
However, this may have been caused by non-specific toxicity since treatment with a 
mutant PNA had similar effects. In conclusion, it appears that HPV 11 or HPV 18 E6 has 
different biological effects and that down regulating HPV 18 E6 expression may negatively 













1.1 Oesophageal cancer 
Oesophageal cancer is the eighth most common cancer (Parkin et at., 2005) and the sixth 
leading cause of cancer death worldwide (Tew et at., 2005; Parkin et at., 2005). In South 
Africa, it is the third leading cancer in males with a lifetime risk of developing the disease 
being I in 73 (Mqoqi et aI., 2004). There are two common types of oesophageal cancer, 
namely adenocarcinoma and squamous cell carcinoma. Adenocarcinoma originates in 
glandular tissue that is not usually present in the lining of the oesophagus and can only 
develop once glandular cells have replaced a section of squamous epithelial cells . This 
condition is called Barrett's oesophagus and develops when there is chronic acid reflux 
from the stomach. This type of oesophageal cancer is more commonly found in developed 
countries and is rare in developing countries such as South Africa (Kwong, 2005). 
Squamous cell carcinoma of the oesophagus originates in the squamous epithelium that 
lines the oesophagus. Figure 1.1 shows that the OSCC protrudes from the submucosal 
layer causing obstruction of the oesophageal lumen. This type of oesophageal cancer is 
more prevalent in developing countries such as South Africa and other countries such as 
China, Japan, Iran, India and Brazil (Kwong, 2005 ; Parkin et at., 2001). 
epiglottis 
oesophageal cancer 
-MJ-o/JtII- - oesophageal lumen 
Figure 1.1: Diagram showing squamous cell carcinoma of the oesophagus. This 
diagram shows a longitudinal section of an OSCC in the upper third of the oesophagus. 
The tumour protrudes from the submucosal layer causing obstruction of the oesophageal 











Oesophageal squamous ce1l carcinoma shows great variability in its distribution worldwide 
and is generally a disease of developing or underdeveloped countries and this is illustrated 
in Figure 1.2. Areas that have a high risk for osee are clustered along the eastern coasts 
of both Africa and South America and in most of Asia and Eastern Europe. In South 
Africa, osee is highest in the Transkei region in the Eastern eape Province. A study 
published by Somdyala et al. (2003) showed that the mean annual age-standardised 
incidence rate of osee in Transkei was 76.611 00 000 for males and 36.511 00 000 for 
females, compared to a global age standardised rate of 11.511 00 000 for males and 
4.71100000 for females (Parkin et aI., 2005). 
The incidence of osee shows a gender difference in its distribution but is generally more 
common in males than females (Parkin et aI., 2005; Somdyala et aI., 2003). It is recorded 
to be about 7-fold more common in males in Eastern Europe (Parkin et al., 2005). In 
Africa, the high incidence osee belt stretches along the east coast from South Africa, 
through Mozambique and Tanzania and up to Kenya and incidentally these regions are 
predominantly maize-consuming areas (Sammon, 1992; Wakhisi et al., 2005 ) . 
• " 1.9 " 3.2 .:.5.9 <. 10.0 • ,,38 .7 
Figure 1.2: The global incidence of oesophageal cancer in males. The different colours 
show the age-standardised rate of osee in males (Parkin et aI., 2001). 
The mortality rate for osee is very high with a 5-year overall global survival rate 
estimated at around 14% (Tew et aI., 2005). There are many reasons for the low survival 











This is due to lack of early symptoms and no screening programmes. It is estimated that 
over 50% of osee patients present with unresectable disease and distant metastases (Tew 
et aI., 2005). In most cases the patients become aware of the tumour when it starts to 
obstruct passage of food and also when they experience difficulties or pain in swallowing. 
At this late stage the tumour would have grown very large and often would have spread to 
other organs. In order to improve early detection of osee and treatment, it is important to 
understand the factors that are associated with this disease. 
1.2 Risk factors associated with oesophageal squamous cell carcinoma 
The development of osee is a complex, multistep process with a multifactorial aetiology. 
The disease is associated with several environmental, dietary and genetic risk factors. 
Excessive tobacco smoking and alcohol consumption have been associated with osee in 
many different populations (Wu et aI., 2006; Pacella-Norman et a!., 2002; Syrjanen, 2002; 
Pinto et al., 2003; Dandara et al., 2005, Dandara et aI., 2006). It has been observed that 
with respect to tobacco smoking,. the critical factors are duration of smoking and amount of 
tobacco smoked. Individuals who started smoking at an earlier age, smoked for a long 
duration, or smoked large amounts of cigarettes per day, had a significantly increased risk 
of developing osee (Wu et al., 2006; Dandara et al., 2006). Similarly, individuals that 
start consuming alcohol at a young age and consume it for a long duration have an 
increased risk of developing osee (Wu et al., 2006). 
The association of high incidence osee areas with maize consumption is one factor that 
has received considerable attention. It is thought that contaminants in the maize used for 
making home-brewed beer could be the source as the maize is sometimes contaminated 
with fungal toxins produced by Fusarium species. From this observation it has been 
postulated that fungal toxins such as aflatoxins and fumonisins could be risk factors for 
developing osee (Mqoqi et al., 2004). In some areas consumption of very hot beverages 
or food have been associated with increased risk as this is thought to irritate and cause 
inflammation in the oesophagus (eastellsague et a!., 2000; Phukan et a!., 2001, Hung et 
aI., 2004). 
Nutritional deficiencies have also been associated with increased risk of developing several 












Generally it has been reported that individuals regularly eating fresh fruit and vegetables 
have some protection from developing osee. A study by De Stefani et al. (2005), 
conducted in Uruguay, showed that consumption of total fruits were more protective than 
total vegetables, and furthermore, citrus fruits compared to other fruits had an associated 
reduced risk for osee. Conversely, in Dafeng, China, high consumption of pickled and 
dried fish and seafood products and eating fast was associated with significantly elevated 
risk of developing osee (Wu et al., 2006). 
Commenting on the distribution of osee in the world, there is a clear picture that the risk 
of osee is inversely associated with socioeconomic status (Wu et aI., 2006). High 
incidence areas are mostly inhabited by the poorest communities in the world (Figure 1.2). 
These areas are occupied by people in low socio-economic groups, characterised by low 
levels of education. There are also other lifestyle factors, such as the use of wood and 
charcoal for cooking or keeping warm, which have been shown to be associated with 
increased risk of osee (Dandara et al., 2006). Families in lower socio-economic groups 
regularly burn wood and charcoal inside their homes, frequently exposing themselves to 
many different compounds released during combustion of the wood. There is a need to 
identify the causative agent(s) that may be released during the burning of the wood and 
may affect the oesophageal epithelium, ultimately leading to the development of squamous 
cell carcinoma. 
Surprisingly, in areas where people are exposed to certain types of carcinogens, not all 
individuals exhibit the same risk profiles, some tend to be more susceptible to developing 
cancer. Most environmental carcinogens need prior activation in order to exert their 
effects. The system of enzymes responsible for this activation have been shown to exhibit 
genetic polymorphisms resulting in certain individuals carrying certain genetic variants 
that make them more susceptible to osee. Different variants have been shown to be 
associated with osee risk in different populations (Pinto et aI., 2003; Lin et aI., 1998; 
Dandara et aI., 2005; Dandara et aI., 2006). 
For example, cytochrome P450 enzymes oxidise several tobacco-smoke and alcohol-
related carcinogens making them more reactive and · able to bind to cellular 
macromolecules, a process that can lead to cancer formation. However, the body expresses 












intennediates from the body. Thus, individuals carrying variants of cytochrome P4S0 that 
increase fonnation of activated intennediates and variants of glutatione S-transferases that 
decrease conjugation are likely to be at an increased risk of OSCC (Taningher et aI., 1999). 
A study by Dandara et al. (200S) showed that in some genetic backgrounds or 
environmental conditions, potentially high cytochrome P4S0 3AS (CYP3AS) activity may 
increase OSCC risk, possibly due to the fonnation of reactive intennediates. The study 
further reported that the nonnal CYP3AS genotype was significantly associated with 
increased risk for OSCC among cigarette smokers and alcohol consumers, while no 
difference was observed among non-smokers and non-alcohol conswners. This 
observation supports the possible involvement of CYP3AS in the activation of 
carcinogenic constituents of tobacco smoke and alcohol. 
In different areas there are several cultural practices that have been associated with 
increased risk of OSCC and these include areca-chewing among Taiwanese (Wu et aI., 
2004) and the habit of self-induced vomiting as a cleansing ritual among Black South 
Africans (Sammon, 1992). Infectious agents have also been associated with OSCC in many 
different geographical regions, particularly infection with the human papillomavirus (HPV) 
(Matsha et al., 2002; Cooper et aI., 1995, Williamson et al., 1991; Chang et aI., 1990; 
1992; 2000; Farhadi et aI., 200S; Katiyar et aI., 200S; Furihata et al., 1993). HPV 
infection and its role in OSCC susceptibility is a focus of this project. 
1.3 Human papillomavirus and oesophageal squamous cell carcinoma 
Hwnan papillomavirus is a well-known aetiological agent for cervical cancer. There are 
more than 100 types of HPV s, with some of them being classified as low- and high-risk 
types depending on their association with causing cervical cancer (Motoyama et al., 2004). 
Epidemiological studies are starting to show that there could also be a role for HPV in 
OSCC. The first association between HPV infection and OSCC was suggested in 1982 by 
Syrjanen et al. (1982). Since then, many studies have been published with conflicting 
results showing that the percentage of OSCC with HPV DNA present in the tumour cells 












gene as PCR is more sensitive than in situ hybridisation and the HPV E6 gene is always 
conserved after viral integration (Sur and Cooper, 1998). 
A study by Williamson et at. (1991) using nested PCR to detect HPV L1 DNA showed that 
71% (10/14) of the OSCC biopsies harboured HPV DNA compared to only 15% (6/41) of 
biopsies from patients without oesophageal malignancy. The sample size for the study was 
very small (only 14 OSCC biopsies were tested) therefore the results may not be a true 
reflection on the population studied. However, they further showed that 43% (6/14) of the 
OSCC biopsies contained HPV and 66% (6/9) of the adjacent tissue were HPV positive. 
They noted that no tumours were HPV positive without the adjacent tissue being positive. 
Moreover, in some cases the tumour cells were negative for HPV DNA but the adjacent 
tissue was positive. This could indicate that the viral DNA in the tumour cells had 
integrated in the host genome, via disruption of the HPV L 1 gene, therefore giving a false 
negative result. They hypothesised that the viral DNA in the normal adjacent tissue is still 
episomal with the HPV L 1 gene intact. 
The association between HPV infection and OSCC is high in areas with a high incidence 
of OSCC such as South Africa, China, and Iran and low in low incidence areas such as 
USA (Turner et at., 1997), UK (Morgan et ai., 1997), Hong Kong (Loke et ai., 1990) and 
the Netherlands (Kok et at., 1997). The variation in the association between HPV and 
OSCC may be due to a combination of environmental factors, geographic location or 
genetic susceptibility to oesophageal HPV infection in different populations (Sur and 
Cooper, 1998). 
1.4 Human papillomavirus 
Human papillomaviruses are small, double-stranded DNA viruses that infect mucosal and 
cutaneous epithelial tissue. They are non-enveloped viruses with icosohedral capsids 
(Longworth and Laimins, 2004). The HPV genome is approximately 8 kb in size encoding 
6 early proteins, E1, E2, E4, E5, E6 and E7, and two late proteins, L1 and L2 (Figure 1.3). 
The proteins are expressed from polycistronic mRNAs which are transcribed from a single . 











The HPV Eland E2 genes are the first to be expressed and encode proteins that are vital 
for extrachromosomal DNA replication and the completion of the viral life cycle 
(Motoyama et al. , 2004). HPV El and E2 form a complex and bind to sequences at the 
viral origin of replication. This binding acts to recruit cellular polymerases and accessory 
proteins that are necessary to mediate replication of the viral DNA. In addition, HPV E I 
exhibits helicase activity and functions to separate viral DNA strands ahead of the 
replication complex (Longworth and Laimins, 2004). HPV E2 also plays an important role 
in regulation of viral transcription from the early promoter. At low concentrations, HPV 
E2 binds adjacent to the early promoter and activates transcription, while at high levels, it 
represses transcription of the early genes, including HPV E6 and E7, by blocking the 
binding of cellular transcription factors. This allows HPV E2 to control the viral copy 
number in undifferentiated cells as both HPV E1 and E2 are expressed from the early 
promoter (Longworth and Laimins, 2004). 
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Figure 1.3: Organisation of the human papillomavirus genome. The HPV genome is 
8 kb in size and is divided into three regions, the non-coding long control region (LCR), 
and the protein-coding early (E) and late (L) gene regions. The virus encodes six early and 
two late proteins. Most HPV mRNAs are polycistronic, and many carry three or more 
open reading frames (10 and Kim, 2005). 
The functions of the HPV E4 and E5 proteins are not fully understood, however they have 
both been implicated in regulation of late viral function (Longworth and Laimins, 2004). 
HPV E4 is only expressed in the later stages of infection when complete virions are being 
assembled (Jo and Kim, 2005) and it is thought to playa role in maturation and replication 











function may not be important in maintaining the malignant transformation of the host cell 
(Motoyama et al., 2004). 
The HPV E6 and E7 genes encode oncoproteins that are involved in the transformation of 
host cells (will be discussed later). In addition, HPV E6 and E7 proteins have been shown 
to be necessary for maintaining the HPV genome extrachromosomally in undifferentiated 
basal cells (Longworth and Laimins, 2004). The two late genes, HPV LI and L2, encode 
for the viral structural proteins that form the icosahedral viral capsid consisting of 72 
capsomers (10 and Kim, 2005). The virions are packaged in the cell and then released 
from the uppermost layers of the epithelium. The non-coding, long control region (LCR) 
of 400 to 1 000 bp has many overlapping binding sites for activators and repressors of 
transcription and this region is thought to playa role in determining the host range for 
specific HPV types (Motoyama et at., 2004). The LCR regulates transcription of the early 
and late regions, therefore controlling viral protein and virion production (10 and Kim, 
2005). 
1.5 The role of human papillomavirus in cancer 
Human papillomavirus is associated with several cancers, the most common and best 
studied being cervical cancer. It is now accepted that HPV is the causative factor for 
cervical cancer as at least 99% of the cervical cancer cases have an HPV aetiology 
(Longworth and Laimins, 2004). Reports have been published supporting an etiologic role 
for HPV in other cancers including breast cancer (de Villiers et al., 2005), squamous cell 
carcinoma of the head and neck (Ferris et at., 2005) and anogenital cancer (Finzer et at., 
2002). 
Approximately 118 different types of HPV have been identified, with limited DNA 
homology (10 and Kim, 2005). The different HPV types are divided into two categories, 
the high- and low-risk types, depending on their association with causing cervical cancer 
(Longworth and Laimins, 2004). The high-risk types include types 16, 18,31,33,35,39, 
45, 50, 51, 53, 55, 56, 58, 59, 64 and 68 and these types are commonly detected in 
carcinomas and dysplasias (Motoyama et al., 2004). The low-risk types include types 1, 6 
and 11 and these are usually associated with causing benign warts and lesions which rarely 











However, the so-called "low-risk" types, specifically types 6 and 11, have also been 
identified in penile cancer (Dianzani et aI., 1998), laryngeal and bronchogenic carcinomas 
(Reidy et aI., 2004) as well as OSCC (Cooper et aI., 1995; Matsha et ai., 2002; Chen et aI., 
1994). Reidy et ai. (2004) detected HPV 11 in 100% (9/9) of patients with laryngeal or 
bronchogenic carcinomas that had developed due to recurrent respiratory papillomatosis. 
They concluded that HPVll is an "aggressive virus in laryngeal cancer". 
A study by Chen et al. (1994) using specimens from Fuzhou, a high-risk area in Southern 
China, found that 24/40 (60%) of the oesophageal biopsies tested were HPV positive and 
out of the HPV-positive tumours, 50% contained HPV 6 DNA. HPV16 was detected in 
8% (2/24) of the HPV-positive biopsies and dual infections with HPV types 6 and 16 were 
detected in 17% (4/24) of the HPV-positive biopsies. The HPV type was unknown in 25% 
(6/24) of the samples. Furthermore, a study performed by Matsha et al. (2002) showed 
that HPV 11 was the dominant type accounting for 48% (11/23) of the HPV -positive OSCC 
patients in Transkei, South Africa. The other HPV types identified in that study were 
HPV39 (30%), HPV16 (9%), HPV52 (4%) and unknown (9%). It is therefore necessary to 
determine whether the categorised "low-risk" HPV types playa role in the development of 
tumours or whether they are merely bystanders in the tumorigenic process. 
1.6 The human papiUomavirus I fecycle 
Human papillomaviruses that infect the genital region are mostly sexually transmitted, but 
infection is not limited to the genital tract as approximately 20% of cancers of the 
oropharynx contain high-risk HPV DNA. It is estimated that two-thirds of individuals who 
have sexual intercourse with an HPV -infected partner will contract the virus, however 
most people clear the infection within a year (Longworth and Laimins, 2004). The 
receptor for entry of the virus into cells is currently unknown, however heparin sulphate 
(Longworth and Laimins, 2004) and stabilising proteoglycans (10 and Kim, 2005) have 
been suggested to mediate the initial attachment of virions to epithelial cells. 
If the virus initially infects differentiated, more superficial cells, the infection will usually 
be transient, since the viral DNA will be lost as the infected cells are shed during terminal 
differentiation. However, if the virus infects proliferating basal cells of the squamous 











accesses and infects the basal layer cells through microwounds of the epithelium that 
expose the basal cells (Longworth and Laimins, 2004). In oesophageal epithelium, 
microwounds could be due to consumption of very hot drinks, the use of emetics and 
exposure to tobacco smoke which may constantly irritate and damage the oesophageal cells 
allowing HPV entry into the basal epithelial cells . 
The viral lifecycle of HPV is linked to the differentiation programme of the infected host 
cell, the keratinocyte, and can be separated into two stages, the non-productive and 
productive stage. In persistent infections, the infected basal cells usually have monomeric 
episomes that co-replicate with the genome of the host cells (the non-productive stage). 
There are usually between 20 and 100 extrachromosomal copies of viral DNA per cell 
(Longworth and Laimins, 2004). When the infected cell undergoes differentiation, the 
productive stage of the life cycle starts (Figure 1.4). Viral transcription, particularly of the 
HPV E6 and E7 oncogenes, is markedly increased and vegetative DNA replication and 
assembly of new virions occur. 
A 
Figure 1.4: Schematic representation of the HPV lifecycIe. A) Productive HPV 
lifecycle. Nuclei expressing HPV E6 and E7 are indicated in blue. Viral episomes are 
indicated as black circles and viral capsid proteins are indicated in red . Virions are 
depicted as black circles in red, icosahedral structures. B) Deregulated HPV E6 and E7 
expression in proliferating basal cells associated with cell transformation and failure of the 











Once the terminally differentiated cells are shed, the newly packaged viruses are 
simultaneously released (Figure 1AA). If the HPV E6 and E7 expression remains 
differentiation-dependent there is a very low-risk of the cells becoming transformed as the 
oncogenes will only be expressed in cells that are terminally differentiated. However 
transformation of cells may occur when there is an increase in HPV E6 and E7 expression 
in proliferating cells (Figure lAB). The mechanisms behind this deregulated expression 
are poorly understood (Snijders et at., 2006). 
Deregulation of HPV E6 and E7 expression in the basal cells is associated with cell 
transformation and failure of the viral life cycle. The viral genome may integrate into the 
host genome usually disrupting the HPV E1 and E2 open reading frames. This leads to an 
increase in HPV E6 and E7 levels as E2 can no longer repress transcription of the 
oncogenes (Finzer et at., 2002). HPV integration terminates the viral lifecycle because 
large portions of the viral genome are disrupted and are therefore functionally inactive (10 
and Kim, 2005). The majority of HPV -positive cervical cancer tumours have integrated 
HPV DNA and once the viral DNA has integrated into the host genome it is more 
oncogenic due to HPV E6 and E7 overexpression (Motoyama et at., 2004). HPV 
integration sites appear to be randomly distributed over the whole genome. There is 
currently no evidence supporting targeted disruption of critical cellular genes by the 
integrated viral genomes (10 and Kim, 2005). 
A study in South Africa using non-isotopic in situ hybridisation showed that all 
HPV DNA-positive oesophageal cancer biopsies harboured the virus in an integrated state 
(Cooper et at., 1995). This indicates that the presence of HPV in the oesophageal cells 
may playa role in the development of a tumour as the viral DNA has integrated and is 
therefore more oncogenic as the E6 and E7 oncoproteins will be overexpressed. The 
deregulation of HPV E6 and E7 expression in proliferating cells can cause many changes 
in the cells and ultimately lead to the development of tumours (Snijders et at., 2006). 
Since it has been shown that HPV E6 expression alone can lead to transformation of the 
host cell (Gao et at., 1997; Sedman et at., 1992; Kiyono et ai., 2001), this project focussed 
solely on the affects of HPV E6 from either the high-risk HPV 18 or the low-risk HPV 11 to 











1.7 The effects of high- and low-risk HPV oncoproteins on cellular transformation 
The two oncoproteins encoded by HPV, namely E6 and E7, are involved in transformation 
of host cells. The HPV E6 and E7 proteins are about 160 and 100 amino acids in size, 
respectively (Munger and Howley, 2002). The HPV E7 oncoprotein has been shown to 
bind to the retinoblastoma protein, pRb and inactivate it by preventing it from binding the 
transcription factor E2F (Dyson et ai., 1989). pRb in its active form is 
hypophosphorylated and inhibits S phase entry by binding the transcription factor, E2F. 
Figure 1.5 shows that during normal G1 progression, pRb is sequentially phosphorylated 
by cyclin D1 /cdk4 and 6 and cyclin E/cdk2 complexes causing pRb to dissociate from 
E2F. E2F is therefore free to promote expression of its target genes involved in S-phase 
progression and the cell enters S phase (Munger and Howley, 2002; Jo and Kim, 2005). 
HPV E7 inactivates pRb function by binding to hypophosphorylated pRb, therefore 
preventing it from binding E2F, resulting in S phase entry (Figure 1.5). HPV-E7-
expressing cells therefore continually traverse the cell cycle, leading to an increase in 
cellular proliferation (10 and Kim, 2005) . HPV E7 also induces degradation of pRb via the 
ubiquitin-proteasome pathway indicating a second mechanism of how the viral HPV E7 
protein inactivates pRb function resulting in S phase entry (Boyer et at., 1996). 
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Figure 1.5: HPV E7 inactivates the retinoblastoma protein (PRb). Sequential 
phosphorylation of pRb by cyclinlcdk complexes prevents pRb binding the transcription 
factor, E2F. This results in the dissociation of the pRb/E2F complex resulting in S phase 
entry. HPV E7 binds hypophosphorylated pRb and similarly disrupts the complex between 
pRb and E2F reSUlting in the liberation of E2F. This allows the cell to enter S phase of the 











Malanchi et al. (2004) recently showed that HPV E6 is also capable of inactivating pRb 
function through a different method to that of HPV E7. They showed that both the low-
risk (HPV 1) and high-risk (HPV 16) E6 proteins promote phosphorylation of the pRb 
protein, therefore preventing it from binding E2F and allowing E2F to activate its target 
genes. Thus both the low and high risk E6 proteins had the ability to functionally 
inactivate the pRb pathway in HPV E6-expressing primary human cells and therefore alter 
regulation of the cell cycle. 
The high-risk HPV E6 oncoproteins have also been shown to form a trimeric complex with 
the cellular ubiquitin ligase, E6-associated protein (E6AP) (Zanier et al., 2005), and the 
tumour suppressor protein, p53 (Werness et at., 1990) (Figure 1.6). The formation of this 
trimeric complex causes the E6AP to polyubiquitinate the p53 protein therefore increasing 
the rate of degradation of p53 via proteasomal degradation by the 26S proteasome 
(Werness et at., 1990). This is detrimental to the cell as the role of p53 is to safeguard the 
integrity of the genome by inducing G 1 cell cycle arrest or apoptosis in the presence of 
DNA damage or cell stress. These stresses will therefore result in increased p53 levels in 
normal cells (Kumar and Klark, 2002). As p53 levels cannot be increased in HPV-infected 
cells, the cells continue to proliferate regardless of the integrity of their DNA, allowing 
accumulation of DNA mutations (Havre, 1995; Kessis et al., 1993) and chromosomal 
instability (Schaeffer et al., 2004; Thomas and Laimins, 1998) which is thought to be an 
essential part of malignant transformation. 
The low-risk HPV E6 oncoproteins have been shown to bind with very low affinity to p53, 
if at all, but not increase its rate of degradation (Slebos et al., 1995). In HPV 11-E6-
expressing cells, accumulation of p53 after DNA damage is still intact and the cells are 
able to undergo G] cell cycle arrest in response to DNA damage (Slebos et ai., 1995). 
Futhermore, Zanier et al. (2005), showed that low-risk HPV E6 proteins do not bind E6AP 
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Figure 1.6: HPV E6 causes increased degradation of p53. DNA damage induces p53 
activation, leading to cell cycle arrest or apoptosis. The high-risk HPY E6 binds E6AP and 
p53, forming a trimeric complex. The complex formation results in E6AP-mediated 
ubiquitination and rapid proteasomal degradation of p53, therefore preventing growth 
arrest or apoptosis in response to DNA mutations (Picture from Jo and Kim, 2005). 
The high-risk HPY E6 protein, HPY16 E6, also prevents apoptosis in a p53-independent 
mechanism. This is achieved by the HPY16 E6 protein decreasing Bax mRNA levels, 
shortening the half-life of the Bax protein and stimulating the degradation of the Bax 
protein in human keratinocytes (Magal et at., 2005). Since Bax is a proapoptotic protein 
that enhances apoptosis (Kumar and Clark, 2002), the HPY E6 protein binds and inhibits 
Bax-induced apoptosis thus preventing programmed cell death and resulting in 
accumulation of DNA mutations (Magal et at. , 2005) 
The high-risk HPY E6 proteins also target several other cellular proteins for degradation in 
a manner similar to that of p53 degradation. The high-risk E6 proteins contain a PDZ 
domain protein binding motive and can bind a number of cellular PDZ-domain-containing 
proteins such as hDlg (the human homologue of the Drosophilia melangaser tumor 
suppressor protein discs large) (Kiyono et ai., 1997), MUPPI (a multi-PDZ domain 
protein) (Lee et ai., 2000) and hScrib (the human homologue of the Drosophilia 
melangaser tumor suppressor scribble) and target them for proteolysis via E6AP-mediated 
ubiquitination. The low-risk HPY E6 proteins lack the PDZ binding site and therefore 












High risk HPV E6 mRNA transcripts are alternatively spliced leading to the production of 
a smaller HPV E6 protein, named E6* (Ingaki et at, 1988; Vaeteewoottachern et at., 2005; 
Stacey et at., 1995; Sedman et at., 1991; Schneider-Gadicke et at., 1988). This 
phenomenon has been observed in the high risk HPV types, but no study has shown 
alternatively spliced HPV E6 mRNA in the low-risk HPV types, including HPVll E6 
(Stacey et at., 1995; Sedman et at., 1991; Schneider-Gadicke et at., 1988). Comparison of 
the nucleotide sequence necessary for splicing for the HPV E6 mRNA by Schneider-
Gadicke et at. (1988) showed that the low risk HPV types, i.e. HPV 1, 6 and 11, are 
unlikely to be spliced as they lack the essential dinucleotides (GT) of splice consensus 
sequences that are present in the high risk types, HPVI6, 18,31 and 33. 
The HPV18 E6* protein is only 6.5 kDa in size compared to the full-length E6 proteins 
which are roughly 18.9 kDa (Schneider-Gadicke et at., 1988). The alternatively spliced 
HPV E6 mRNA has been reported to be in abundance, with the full length HPV E6 
transcripts present at very low levels (Zheng and Baker, 2006; Smotkin and Wettstein, 
1986). The E6* proteins negatively regulate the expression of the active, full-length HPV 
E6 proteins therefore contributing to low HPV E6 protein levels (Sedman et at., 1991). 
Since only the high-risk HPV E6 mRNA is spliced, it was previously thought that perhaps 
the HPV E6* may be associated w th transforming activity. However, several studies have 
shown the opposite (Pim et at., 1997; Sedman et at., 1991). Pim et at. (1997) showed that 
the HPV E6* protein inactivated the function of the full length HPV 18 E6 protein. They 
showed that the HPV18 E6* protein can bind to both the full-length HPV E6 protein and 
the E6AP, in vitro. This binding results in the E6* protein inactivating the function of the 
full-length HPV18 E6 protein by preventing it from binding p53, in vitro and in vivo. The 
trimeric complex consisting of HPV18 E6, E6AP and p53 is therefore unable to form and 
hence p53 will not be polyubiquitinated and degraded. 
Pim et at. (1997) also showed that increased expression of HPV E6* in HPV -positive 
transformed cells lead to an increase in transcriptional activity of p53 resulting in a 
decrease in transformed cell growth. Sedman et at. (1991) reported that the HPV 16 E6* 
protein had no transforming activity and functioned to facilitate HPV E7 translation from 











active E6* proteins. However, Stacey et al. (1995) showed conflicting results and reported 
that the alternatively spliced HPV E6 mRNA did not increase HPV E7 translation. 
The high-risk HPV E6 oncoproteins are capable of immortal ising the host cell. Normal 
human keratinocytes have a finite proliferative lifespan and enter senescence within 50-
100 cell divisions due to telomere shortening (Snijders et aI., 2006). HPV E6 prevents 
telomere shortening and hence senescence by activating hTERT, the catalytic subunit of 
telomerase, the enzyme which is responsible for maintaining telomere length at the 3' end 
of the chromosome. HPV E6 achieves this by forming a complex with the E6AP and 
binding directly to the hTERT promoter thus activating transcription of the gene (Seo et 
aI., 2004; Gewin et aI., 2004). Furthermore, it has recently been proposed that the 
E61E6AP complex targets NFXI-91, a newly identified repressor of telomerase, for 
ubiquitination and degradation and in so doing activates telomerase activity (Gewin et aI., 
2004). The low-risk HPVll genome is unable to immortalise cells, however it has been 
shown to be capable of extending the lifespan of the cells, grown as mono layers, to over 
three months without undergoing senescence (Thomas et al., 2001). 
Thomas et al. (2001) also showed that HPV 11 altered the patterns of differentiation, 
similar to high-risk HPV s. In normal keratinocytes, nuclei are lost when cells differentiate, 
while in cells expressing high-risk HPVs, nuclei are maintained throughout the suprabasal 
layers. Thomas et al. (2001) reported that cells containing the low-risk HPVll DNA 
similarly demonstrated an altered differentiation pattern compared to cells lacking the 
virus. However, the changes appeared less severe than those seen in cells infected with the 
high-risk HPV31. In the HPV II-expressing cells, nuclei were maintained throughout all 
differentiated layers, however the degree to which nuclei were retained depended on the 
HPVll copy number within the cells. In addition, the cells with a higher HPVll copy 
number were more likely to amplify HPVll DNA, as was observed in cells containing 
high-risk HPV DNA, than cells with a lower copy number. 
The same HPV II-expressing cells were used for microarray analysis to identify genes that 
were differentially expressed in cells containing low- (HPV 11) or high-risk (HPV31) HPV 
types. Five genes that were repressed and 76 genes that were activated (by 2-fold or more) 
by HPV 11 were identified. Only a few sets of genes were similarly activated by both the 











high-risk HPV types target distinct sets of cellular genes and pathways. Some of the genes 
that were highly activated by HPVII were members of the interferon-inducible family. 
Other genes found to be markedly increased in HPV II-containing cells included 
transforming growth factor ~-induced 86 kDa protein, defensin, desmoglein, Stat-I and 
COX2 (Thomas et at., 2001). This study only looked at the gene expression levels in 
proliferating monolayer cultures and not differentiating cells, so it is possible that 
additional changes in cellular gene expression occur during differentiation. 
Research by Shen et at. (2000; 2001; 2003; 2004) has demonstrated that the high-risk 
HPV 18 E6 and E7 proteins together are able to immortalise and malignantly transform 
human embryonic oesophageal epithelial cells. Their results showed that the HPVI8 E6 
and E7 oncoproteins are sufficient to cause telomerase activation, changes in cell 
morphology, anchorage-independent growth, increased cell proliferation, chromosomal 
instability and malignant transformation of oesophageal epithelial cells. This leads one to 
believe that HPV may playa causative ~role in the development of OSCC. A review by Sur 
and Cooper (1998) suggested that there may be a synergistic action between HPV and 
other carcinogenic agents and that the exposure to carcinogens in the diet or environment 
may augment the transformation process initiated by the viral HPV E6 and E7 proteins. It 
is known that exposure to cigarette smoke, alcohol, nitrosamines and mycotoxins can result 
i~ inactivation of the p53 and pRB genes through different mechanisms such as gene 
rearrangements, allelic losses or missense mutation and this may work together with the 
virus to ultimately form a tumour (Sur and Cooper, 1998). 
Besides studies investigating the roles of different HPV proteins in cancer development, 
there is a large area of research concentrating on investigating the effects of knocking out 
HPV genes in HPV-positive cells. Several methods are being used and these include short 
interfering RNA and the use of peptide nucleic acids (PNAs). 
1.8 Peptide nucleic acids as a potential antiviral agent 
The treatment for OSCC is usually individualised with respect to the patient's twnour 
stage, site of the twnour, general health of the patient and the patient's desire for treatment 
(Mackay et at., 2006). Cisplatin-based chemoradiation or surgery are frequently 











metastasised (Tew et aI., 2005). However, it has recently been shown that preoperative 
chemoradiation provides a good treatment strategy for patients with a good performance 
status (i.e. those who can handle aggressive treatment) (Schneider and Urba, 2006). 
Chemotherapy is used to shrink large, inoperable tumours, and to treat micro metastases 
early in the course of the disease and thus minimise the risk of distant relapse (Mackay et 
aI., 2006). 
Patients with metastatic or unresectable oesophageal cancer (stage IV) constitute more than 
50% of cases (Tew et al., 2005), and chemotherapy or radiation is administered only to 
shrink the tumour and improve the quality of life (Mackay et aI., 2006). Another 
intervention used for late-stage patients is the use of stents which help keep the oesophagus 
distended to allow passage of food (Boyce, 1993). Many new therapies for OSCC are 
currently in various phase IIII clinical trials and these include monoclonal antibodies 
targeting either the Her2INeu receptors, the epidermal growth factor receptor or the 
vascular endothelial growth factor as well as signal transduction/tyrosine kinase inhibitors 
targeting epidermal growth factor receptor (Tew et al., 2005). 
Peptide nucleic acids (PNAs) designed to target different genes upregulated in cancers are 
also promising with regards to targeted cancer therapies. PNAs were first described by 
Nielsen et at. (1991) and are synthetic structural homologues of nucleic acids with the 
deoxyribose phosphate backbone replaced by repeating N-(2-aminoethyl)glycine units and 
the nucleobases attached through methylene carbonyl linkers (Hyrup and Nielsen, 1996) 
(Figure 1.7a). The PNA molecules are more closely related to peptides and proteins than 
to oligonucleotides (Nielsen, 2001) but can be used to target and down regulate 
transcription or translation of a chosen target gene. 
Peptide nucleic acids were first used as antisense drugs, targeting RNA and preventing 
translation of a specific protein. More recently, anti-gene PNA are being used to prevent 
transcription of a chosen gene (Cutrona et aI., 2000; Cutrona et al., 2003, Boffa et al., 
2007; Braun et al., 2004). PNAs have an uncharged polyamide backbone instead of a 
negatively charged phosphate-sugar backbone and this is thought to increase the thermal 
stability of PNA-DNA duplexes relative to the corresponding DNA-DNA duplexes as 
there is no electrostatic repulsion between the two strands (Hyrup and Nielsen, 1996; 
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Figure 1.7: Peptide nucleic acids. a) Schematic of PNA oligomers. PNAs are synthetic 
structural homologues of nucleic acids with the deoxyribose phosphate backbone replaced 
by repeating N-(2-aminoethyl)glycine units and the nucleobases attached through 
methylenecarbonyl linkers. b) Representation of PNA binding to complementary 
sequence in double-stranded DNA. PNA binds to its target gene forming a strong triple-
stranded helix that DNA helicase is unable to unwind. RNA polymerase therefore cannot 
transcribe the gene leading to a decrease in protein production. 
Peptide nucleic acids recognise and bind to their complementary target in double-stranded 
DNA thus preventing transcription of the targeted gene (Nielsen, 2001) (Figure 1.7b). This 
binding of PNA to DNA may be mediated either through triplex formation or strand 
displacement. It is thought that PNA-mediated arrest of transcription is due to the inability 
of the DNA heIicase to unwind the strong heteroduplexes (Pooga et at., 2000) hence 
preventing transcription and ultimately protein production. PNAs are most effective when 
designed to bind specifically to the target gene as close to the 5' end of the gene as possible 
and to be between 16 and 18 bases in length. The PNAs must also not form any secondary 
structures (Personal communication, Prof. Lidia Boffa, 1ST, Genoa, Italy). 
As PNAs are synthetic pseudopeptides, they are not recognised by either nucleases or 
proteases (Hyrup and Nielsen, 1996; Pooga et at., 2000) and are stable in serum and cell 
extracts (Dean, 2000). This is favourable for their use as potential therapeutic agents. 
Braun et at. (2004) tested four different PNAs, three designed to target the HPV18 E6 
gene, and one to target the HPV18 E7 gene, on HeLa-S suspension cells, which are known 
to contain HPV18 DNA (Boshart et at., 1984). Their results showed that PNA targeting 
only HPV E7 did not decrease the proliferation rate of HeLa-S cells. Furthermore, PNAs 











induce apoptosis. The most effective PNA treatment was using a mixture of three PNAs, 
two that target HPV18 E6 and one that targets HPV18 E7. Treatment with the mixture of 
PNAs resulted in a decrease in cell proliferation and an increase in apoptosis. An increase 
in pRb and p53 protein levels was also observed indicating that knocking out HPV E6 and 
E7 is able to restore p53 and pRb function. The cells treated with the mixture of PNAs had 
an altered morphology and lost the ability to grow non-adherently (Braun et at., 2004). All 
the observed changes indicated that the PNA-treated cells were reverting back to a 
"normal", untransformed phenotype. 
A group in China (Wang et al., 2004), tested PNAs designed to target human telomerase 
mRNA. Most tumour cells activate telomerase expression to immortalise the cells and 
prevent senescence, however telomerase is rarely activated in normal cells making it a 
good marker for many malignant tumours. The PNA designed to bind telomerase RNA 
was tested on a gastric cancer cell lines, SGC7901, and was found to successfully decrease 
telomerase protein levels. This decrease lead to a change in morphology of the PNA-
treated cells as well as a decrease in cell proliferation and colony formation. 
Other studies have looked at the use of PNA in treating Burkitt's Lymphoma (BL). In BL 
cells, it has been observed that the c-myc oncogene is often translocated close to the Ell 
enhancer of the Ig gene locus. This translocation causes hyperexpression of c-myc 
resulting in increased cell proliferation (Kuppers and Dalla-Favera, 2001). Cutrona et al. 
(2003) designed PNAs complementary to the enhancer Ell intronic sequence (PNAEIl), 
that would selectively block expression of the c-myc oncogene under Ell control but not of 
other c-myc alleles. The PNAEIl had an added nuclear localisation signal to aid uptake 
into the nucleus. 
The PNAEIl was tested in SCID mice where a human tumour was established by 
inoculation of cells from a BL cell line. Treatment with PNAEIl was able to block tumour 
growth in SCID mice inoculated with the human BL cell lines (Boffa et at., 2007). The 
tumours in the mice treated with PNAEIl contained areas of cell necrosis particularly 
around the blood vessels. The inhibition of tumour growth was specific as it was not 
observed in mice treated with PNAEllmut (carrying sequence mutations) or in BL cell lines 
when c-myc was not translocated and therefore not under control of the Ell enhancer (Boffa 











particularly in the BL tumour mass, which is favourable for potential therapeutic drugs 
(Boffa et ai., 2005). 
The above examples show some advances in PNA studies and suggest that PNAs show 
great promise as potential therapeutic agents. In this project, PNAs targeting the HPV18 
E6 gene were used to investigate the effect on cell proliferation. 
1.9 Project objectives and aims 
The main objective of this project was to investigate the role of the low risk HPVll E6 and 
compare it to the high-risk HPV 18 E6 in susceptibility to osee. This objective was 
achieved by introducing either the HPV 11 or HPV 18 E6 genes into HPV -negative cell 
lines, determining whether the gene is transcribed and expressed in the selected stable 
transfectants, and investigating the consequent effects on the cells. HPV 18 E6 expression 
was knocked down in the HPV -positive cell line, HeLa, using PNA to determine if this has 












Materials and Methods 
2.1 Materials 
2.1.1 Expression vectors and peptide nucleic acids 
Human papillomavirus 11 and 18 E6 genes cloned into pcDNA3.1 (+) expression vector 
(Invitrogen, Paisley, Scotland) (Appendix A.3) were provided by Dr Lawrence Banks at 
The International Centre for Genetic Experimentation and Biotechnology, Triest, Italy. 
The peptide nucleic acids were designed and synthesised by Prof Lidia Boffa at the Istituto 
Nazionale per la Ricerca SuI Cancro (1ST), Genoa, Italy. Appendix A contains 
information regarding the DNA and protein molecular weight markers used in this study. 
Appendix B contains the details of all solutions used in the following methods. 
2.1.2 Cell lines and media 
Four different cell lines, namely EPC2-hTERT (EPC2), a telomerase-immortalised 
oesophageal epithelial cell line (Harada et ai., 2003), MCF-12A, a non-tumorigenic breast 
epithelial cell line established from tissue taken at reduction mammoplasty from a 
mulliparous patient with fibrocystic breast disease (Paine et ai., 1992), Ratl fibroblasts 
(A TCC CRL-2210) and HeLa, a known HPV 18-positive cervical cancer cell line (Boshart 
et aI., 1984.), were selected to determine the effects of HPV 11 and HPV 18 E6. EPC2 cells 
were grown in Keratinocyte Serum-Free Media (KSFM) (Invitrogen, Paisley, UK) 
supplemented with 50 Ilg/ml Bovine Pituitary Extract (BPE) (Invitrogen, Paisley, UK), 
1 ng/ml epidermal growth factor (EGF) (Invitrogen, Paisley, UK), 100 U/ml penicillin and 
100 J.lg/ml streptomycin. 
MCF12A cells were grown in 50% Hams F12 medium, 50% Dulbecco's Modified Eagle 
Medium (DMEM), 5% heat-inactivated foetal bovine serum (FBS) (Invitrogen, Paisley, 
UK), 50 U/ml penicillin, 50 Ilg/ml streptomycin, 100 ng/ml cholera toxin (Sigma, 
Ayrshire, UK), 20 ng/ml mouse EGF (Sigma, Steinheim, Germany), 10 Ilg/ml bovine 
insulin (Sigma, Steinheim, Germany) and 500 ng/ml hydrocortisone (Sigma, Missouri, 











heat-inactivated FBS, 100 U/ml penicillin and 1 00 ~g/ml streptomycin. The oesophageal 
cancer cell lines, WHC01, WHC03, WHC05, WHC06, KYSE30, KYSE70, KYSE180 
and KYSE520 (Veale et aI., 1989; Shimata et aI., 1992) as well as the known 
HPVl6-positive cervical cancer cell lines, CaSki (Baker et ai., 1987) were grown In 
DMEM containing 10% heat-inactivated FBS, 100 U/ml penicillin and 1 00 ~g/ml 
streptomycin. 
2.2 Methods 
2.2.1 Cell culture 
Generally, cells were cultured to between 80 and 100% confluence after which they were 
trypsinised using 0.05% trypsin-EDT A. After the cells had detached, the trypsin was 
neutralised with either DMEM containing 10% FBS for all cells except for EPC2 cells for 
which 250 ~g/ml of trypsin inhibitor Type I-S from soybean (Sigma, Steinheim, Germany) 
diluted in sterile phosphate-buffered saline (PBS) was used. Cells were collected by 
centrifugation for 5 minutes at 1000 g (Beckman Model TJ-6 Centrifuge, California, 
USA), resuspended in the corresponding growth medium and replated at a dilution of 
between 1:4 and 1: 10. 
Preparation of frozen stocks involved steps described above, however, instead of replating 
the cells, the cells were counted using a haemocytometer (Marienfeld, Mannheim, 
Germany), centrifuged and resuspended in cell freeze medium at a concentration of 
1 x 1 06 cells/ml. The cell freeze medium contained 10% dimethyl sulphoxide (DMSO), 
20% FBS and 70% DMEM except for the EPC2 cells which were frozen in medium 
containing 10% DMSO and 90% FBS. One millilitre samples were aliquoted into ampules 
and slow freezed to -80°C before transferring to liquid nitrogen for long term storage. 
When required, frozen stocks were thawed in a 37°C water bath followed by centrifugation 
for 5 minutes at 1000 g and the pellet resuspended in 2 ml medium for plating in either 











2.2.2 Preparation and quantification of genomic DNA 
Genomic DNA was prepared from the cells lines, using the method described by Strauss 
(1998), and the presence of HPV DNA was detected using the polymerase chain reaction 
(PCR). The cells were plated in 100 mm dishes and incubated at 37°C in an incubator 
containing 5% CO2. Once the cells were 80-100% confluent, they were harvested by 
trypsinisation, neutralised and then centrifuged for 5 minutes at 1000 g (Beckman Model 
TJ-6 Centrifuge, California, USA) to pellet the cells. The cells were then washed twice by 
resuspension in 10 ml ice-cold PBS and resuspended in 600 )ll digestion buffer. The 
samples were then incubated overnight in a shaking water bath at 50°C. 
An equal volume of phenol:chloroform:isoamyl alcohol (25 :24: 1) was added and mixed by 
vortexing. Samples were centrifuged for 10 minutes at 1 700 g and the resulting aqueous 
layer was transferred to a new tube. The phenol:chloroform:isoamyl alcohol extraction 
was repeated if a large, white interphase was observed. A half volume of 7.5 M 
ammonium acetate and 2 volumes of 100% ethanol were added after which the DNA was 
recovered by centrifugation at 1 700 g for 2 minutes. The pellet was rinsed in 70% ethanol 
and air dried. DNA was resuspended in Tris-EDTA (TE) buffer, and DNase-free 
Ribonuclease A (Fermentas, Maryland, USA) was added to a final concentration of 
1 )lg/ml and incubated at 37°C for 1 hour to degrade contaminating RNA. 
The quality and quantity of DNA was determined spectrophotometrically by measuring 
absorbance (OD) at 260 and 280 run. The formula: DNA concentration ()lg/mI) = OD26o x 
50 )lg/ml x dilution factor, was used to calculate the DNA yield. A known amount of 
DNA was electrophoresed on 1 % agarose containing 0.5 )lg/)ll ethidium bromide to further 
confirm the quality. DNA molecular weight markers were routinely included in all agarose 
gels to determine the approximate sizes of the DNA bands. Appendix A.I shows the 
different DNA molecular weight markers used and the corresponding sizes of the bands. 
2.2.3 peR detection of HPV DNA sequences 
The integrity of the extracted DNA was validated by the amplification of either human or 
rat serum albumin. For the human serum albumin gene, primers 5'-GCC CTC TGC T AA 











93 bp fragment and for the rat serum albumin gene, the primers 5'-TGC CTT TTC TAG 
GGG TGT GT-3' and 5'-CCT GGC TTC CGT TAC TAC GA-3' amplified a 340 bp 
fragment. Generally the reaction mixture contained 20 pmol of each primer, GoTaq® Flexi 
Buffer, 150 ng DNA, 1.5 mM MgCh, 0.2 mM of each dNTP, 1.25 U GoTaq® DNA 
Polymerase and H20 to a final volume of25 Ill. 
The PCR conditions for amplifying rat and human serum albumin consisted of an initial 
denaturation at 95°C for 1 minute followed by 30 cycles of denaturation at 94°C for 
30 seconds, annealing at 60°C (55°C for rat serum albumin) for 30 seconds and extension 
at 72°C for 30 seconds, followed by a final elongation step of 7 minutes at 72°C 
(GeneAmp® PCR system 2700, Applied Biosystems, California, USA). The PCR products 
were resolved on 2% agarose containing ethidium bromide. 
For the detection of HPV, either the HPV L 1 or E6 gene was amplified. Amplification of 
the HPV L1 gene involved using the consensus, degenerate primers MY09 (5'-CGT CCM 
ARR GGA WAC TGA TC-3') and MY11 (5'-GCM CAG GGW CAT AAY AAT GG-3') 
[M=A+C, R=A+G, W=A+T, Y=C+T, S=G+C] to amplify at 450 bp fragment for a wide 
range of HPV types followed by nested PCR with a second set of primers (Manos et ai., 
1989). The PCR mixture for the first amplification reaction consisted of GoTaq® Flexi 
Buffer,2 mM MgCh, 0.2 mM of each dNTP, 20 pmol of each of the MY09 and MY11 
primers, 1.25 U GoTaq® DNA Polymerase, 400 ng genomic DNA and H20 to a final 
volume of 50 ~l. A hot-start PCR was performed by withholding the inclusion of the 
MYl1 primer until the PCR mixture reached 94°C for 1 minute. The samples were then 
denatured for a further 9 minutes at 94°C, followed by 40 cycles of 1 minute at 94°C, 
1 minute at 55°C and 1.5 minutes at 72°C, followed by a final elongation step of 5 minutes 
at 72°C. 
The nested PCR reaction was done in the presence of the non-degenerate GP5+ and GP6+ 
primer set to further improve detection. The no template control from the first 
amplification reaction was reamplified using the nested primers to check for any cross 
contamination. The PCR mixture consisted of GoTaq® Flexi Buffer, 2 mM MgCh, 
0.2 mM of each dNTP, 50 pmol of each of the primers (GP5+: 5'-TIT GTT ACT GTG 
GTA GAT ACT AC-3', GP6+: 5'-CTT ATA CTA AAT GTC AAA TAA AAA G-3'), 











amplification reaction and H20 to a final volume of 50 ~l. The DNA was first denatured 
for 5 minutes at 94°C, followed by 30 cycles of 1 minute at 94°C, 2 minutes at 44°C and 
1.5 minutes at 72°C, followed by a final elongation step of 5 minutes at 72°C. The 
products from the nested PCR were resolved on 2% agarose gels containing 0.5 ~g/~l 
ethidium bromide to detect the 150 bp band. 
For detection of the HPV E6 gene, PCR using the WD set of primers, which consists of 
three forward and two reverse primers, was used. The sequences of the primers are as 
follows: WD72: 5'-CGG TCG GGA CCG AAA ACG G-3', WD76: 5'-CGG TTS AAC 
CGA AAM CGG- 3', WD154: 5'-TCC GTG TGG TGT GTC GTC C-3', WD67: 5'-WGC 
AWA TGG AWW GCY GTC TC-3', WD66: 5'-AGC ATG CGG TAT ACT GTC TC-3'. 
[M= A+C, R=A+G, W-A+T, Y=C+T, S=G+C]. The PCR consisted of GoTaq® Flexi 
Buffer, 2 mM MgCh, 0.2 mM of each dNTP, 10 pmol of WD72, 10 pmol of WD66, 
10 pmol ofWD154, 40 pmol ofWD76, 40 pmol WD67, 2.5 U GoTaq® DNA Polymerase, 
200 ng of genomic DNA and H20 to a final volume of 50 ~l. The DNA was first 
denatured for 5 minutes at 94°C, followed by 40 cycles of 30 seconds at 94°C, 30 seconds 
at 60°C and 30 seconds at 72°C, followed by a final elongation step of 5 minutes at 72°C. 
A positive result was indicated by the amplification of a 240 bp product. 
Polymerase chain reaction was used to detennine whether the transfected cells contained 
the HPV11 or HPV18 E6 gene. Primers specifically amplifying a section of either the 
HPV11 or HPV18 E6 genes were designed using Primer3 (Rozen and Skaletsky, 2000). 
The PCR mix used to amplify the HPV18 E6 gene consisted of GoTaq® Flexi Buffer, 
1.5 mM MgCh, 0.2 mM of each dNTP, 20 pmol of each of the primers (forward 5' -GCG 
ACC CTA CAA GCT ACC TG-3' and reverse 5'-GAG TCG TTC CTG TCG TGC TC-
3'), 1 U GoTaq® DNA Polymerase and 150 ng of genomic DNA in a final volume of25 ~l. 
The PCR conditions involved denaturation for 5 minutes at 95°C, followed by 35 cycles of 
30 seconds at 94°C, 30 seconds at 66°C and 45 seconds at 72°C, followed by a final 
elongation step of 7 minutes at 72°C. The PCR products were analysed on a 1.5% agarose 
gel containing 0.5 ~g/~l ethidium bromide at 3.9 V/cm to detennine the presence of a 
423 bp band. 
The PCR mixture used to amplify the HPV11 E6 gene consisted of GoTaq® Flexi Buffer, 











CCA CGT CTG CAA CAT C-3' and reverse 5'-ATC TCT GCG GTG GTC AGT G-3'), 
1 U GoTaq® DNA Polymerase and 150 ng of genomic DNA in a final volume of 25 I.d. 
The DNA was first denatured for 5 minutes at 95°C, followed by 30 cycles of 30 seconds 
at 94°C, 30 seconds at 60°C and 30 seconds at 72°C, followed by a final elongation step of 
7 minutes at 72°e. The PCR products were analysed on 2% agarose containing 0.5 Ilg/Ill 
ethidium bromide at 3.9 V/cm to detennine the presence ofa 112 bp band. 
2.2.4 Propagation of HPVll and HPV18 E6 clones in E. coli DH5a 
The pcDNA3 vector containing either the HPVll or HPV18 E6 genes were received from 
Dr Lawrence Banks at The International Centre for Genetic Experimentation and 
Biotechnology, Triest, Italy, however we needed to confinn the presence of the correct 
insert. The confinnation was done by transfonning E. coli DH5a bacteria with the vectors, 
extracting plasmid DNA from the transfonned bacteria and confinning the insert by 
restriction enzyme analysis and DNA sequencing. The pcDNA3 vector constructs were 
transfonned into DH5a bacteria to produce sufficient amounts of the plasmids for further 
experiments. Competent bacteria were produced according to the protocol by Maniatis 
et al. (1982) and stocks of the competent cells were made by adding glycerol to a final 
concentration of 10% in Luria broth (LB) and stored at -80°e. 
Competent bacteria (~200 Ill) were transfonned by adding 50 ng ofpcDNA3 plasmid DNA 
(carrying either the HPVll or HPV18 E6 gene or no insert), mixing gently and keeping 
them on ice for 30 minutes. The cells were then heat shocked for 50 seconds in a 42°C 
water bath and then placed on ice for 2 minutes. One millilitre of LB was added to the 
cells, which were incubated at 37°C for a minimum of 1 hour. Thereafter, 50-150 III of the 
transfonned bacteria was plated on Luria agar plates containing 100 Ilg/ml of ampicillin 
(Sigma, Steinheim, Germany). Colonies containing the transfonned plasmid were picked 












2.2.5 Small-scale preparation of plasmid DNA 
Bacterial colonies were picked and grown overnight in 5 ml of LB containing 100 Ilgfml 
ampicillin. The three pcDNA3 vector constructs, pcDNA3, pcDNA3-11E6 or pcDNA3-
18E6, were harvested using the QIAGEN® Plasmid Mini Kit (QIAGEN, Hilden, 
Germany). The protocol was followed as described by the manufacturer. After the 
extraction, 20 Ilg!ml DNase-free Ribonuclease A was added to the plasmid DNA to digest 
any remaining RNA. The plasmid DNA was then quantified as described in section 2.2.2 
and 500 ng was electrophoresed on a 1 % agarose gel containing 0.5 1lg!lll ethidium 
bromide at 3.9 Vfcm to determine the quality of the extracted plasmid DNA. 
2.2.6 Restriction enzyme mapping 
The plasmid DNA was analysed by restriction enzyme digestion to confirm the presence of 
the correct insert in the pcDNA3 vectors. DNAman was used to select a restriction 
enzyme that would differentiate between the HPVll and HPV18 E6 inserts as well as the 
vector lacking an insert. The restriction enzyme AhaIII (Amersham Biosciences, 
Buckinghamshire, UK) was chosen as it cuts the HPV 11 and HPV 18 E6 genes at different 
places producing different sized fragments that can be used to identify the genes. 
Digestions were set up containing 2 Ilg plasmid DNA, 4 U AhaIII, Buffer M (Amersham 
Biosciences, Buckinghamshire, UK) and H20 to a final volume of 30 Ill. The samples 
were digested at 37°C for 2 hours and then resolved on a 1.4% agarose gel containing 
0.5 Ilgflll ethidium bromide at 3.9 V fcm to determine the size of the resulting products. 
2.2.7 Sequencing of the pcDNA3 inserts 
DNA sequencmg was performed using the BigDye Terminator v3.1 kit (Applied 
Biosystems, California, USA). The reaction mixture for the sequencing contained Ready 
Reaction Premix, BigDye Sequencing Buffer, 3.2 pmol T 7 primer, 500 ng of template 
plasmid DNA and H20 to a final volume of 20 Ill. The PCR consisted of 25 cycles of 
30 seconds at 96°C, 15 seconds at 50°C and 4 minutes at 60°C. The PCR products were 
analysed by capillary electrophoresis on an ABI 3100 Genetic Analyser. The identification 











Transfectin™ Lipid Reagent was used for transfecting both MCF12A and Rat1 cells. For 
the MCF12A transfection, 120 000 cells were set up in triplicate in 6-well plates, and 
incubated overnight at 37°C in an incubator containing 5% CO2. One microlitre of 
Transfectin ™ Lipid Reagent was added to 99 ~l of DMEM, lacking any supplements. 
After incubating the mixture for 5 minutes at room temperature, it was added to eppendorf 
tubes containing 500 ng of either the pcDNA3, pcDNA3-11E6 or pcDNA3-18E6 
constructs diluted in 1 00 ~l DMEM. After mixing gently and incubating at room 
temperature for 20 minutes, the mixture was added drop-wise to the cells and left for 
5 hours at 37°C in an incubator with 5% CO2. The medium was changed after 48 hours 
and G418 was added to the cells at a final concentration of 350 ~glml to select for cells 
containing the pcDNA3 vector constructs. 
For Rat1 fibroblasts, cells were plated in triplicate in 100 mm dishes and transfected when 
50 to 60% confluent. For each 100 mm dish, 6 ~l Transfectin™ Lipid Reagent, 3 ~g of 
either pcDNA3, pcDNA3-11E6 or pcDNA3-18E6 were added to 50 ~l serum-free DMEM. 
After mixing gently and incubating at room temperature for 20 minutes, the mixture was 
added drop-wise to the cells and processed as described for the MCF12A cells, with the 
exception that G418 was added at a final concentration of 400 ~g/ml. 
2.2.9 Selection for transfected cells 
Transfected cells were selected for G418 resistance. To detennine the concentration of 
G418 necessary for selection of the various cell lines, 50 000 cells were plated per well in a 
24-well plate and allowed to settle overnight at 37°C in an incubator containing 5% CO2. 
Different concentrations ofG418, ranging from 100 to 1000 ~g/ml for MCF12A and Rat1 
cells and 10 to 200 ~glml G418 for EPC2 cells, were used to detennine the best dose. The 
concentration of G418 that caused substantial cell death within the first 4-5 days and killed 
all the untransfected cells within 2 weeks was used to select for transfected cells. 
For each transfection, G418 was added to a plate of untransfected cells to determine 
whether the drug killed all the cells lacking the pcDNA3 vector. Once all the untransfected 
cells were dead, the concentration of G418 added to the medium was decreased to a 
maintenance dose. The cells were maintained continuously in medium containing the 












Once sufficient cells were obtained, freezes of the cells were made as described in section 
2.2.1. Cells were plated for selection of stable clones by seeding 1 cell per well in 96-well 
plates. 
2.2.10 RNA extraction 
Total RNA was extracted from the transfected EPC2 and Rat! pools 8 to 10 passages after 
transfection to determine the relative HPV 11 and HPV 18 E6 mRNA levels. HeLa cells, 
known to contain HPV 18 DNA, were included as a positive control and cells containing 
only the pcONA3 vector were included as a negative control. Briefly, 500 000 cells were 
plated in triplicate in 60 mm dishes and incubated until 80-90% confluent. The cells were 
washed once with PBS to remove residual medium, trypsinised and neutralised with 
OM EM containing 10% FBS for Ratl cells and soybean trypsin inhibitor for EPC2 cells. 
The cells were centrifuged at 1000 g for 5 minutes and resuspended in 2 ml PBS. The cells 
were then counted using a haemocytometer and 1.2 x 106 cells were aliquotted into clean 
microcentrifuge tubes, centrifuged and resuspended in 200 III PBS. Total RNA was then 
harvested using the High Pure RNA Isolation Kit (Roche, Mannheim, Germany) according 
to the manufacturer's protocol. 
The extracted RNA was quantified by measuring the absorbance at 260 nm and 280 nm 
using a Beckmann Ou650 spectrophotometer (California, USA). The following formula 
was used to calculate the RNA concentration: RNA concentration (Ilg/ml) = 00260 x 
40 Ilg/ml x dilution factor. One microgram of total RNA was diluted in RNA loading dye 
and electrophoresed on a formaldehyde-containing 1.5% agarose gel dissolved in MOPS 
buffer containing 0.5 Ilg/1l1 ethidium bromide. The gel was electrophoresed at a voltage of 
3.6 V/cm for 30 minutes. 
2.2.11 cDNA synthesis 
The RNA/primer mix was prepared by diluting 1 Ilg of total RNA to a final volume of 7 III 
in diethylpyrocarbonate (OEPC)-treated water and adding 500 ng oligo dT(l5) (Promega, 
Wisconsin, USA). The mixture was incubated at 70°C for 10 minutes, centrifuged briefly 
and placed immediately on ice to cool. To the RNA/primer mix was added first strand 











flame-sterilised covers lips (Deckglaser, Germany) and incubated in normal growth 
medium at 37°C in an incubator containing 5% CO2 until 70-80% confluent. Medium was 
then removed and the cells were fixed using 4% paraformaldehyde (PF A) in PBS for 
20 minutes at room temperature. Thereafter, the cells were washed three times in PBS 
(each wash lasting 5 minutes). The cells were permeabilised in 0.5% Triton X-IOO in PBS 
for 5 minutes and then washed three times, as before. The free aldehyde groups were 
subsequently quenched by the addition of 50 mM NH4CI in PBS for 5 minutes and the 
cells then blocked in 0.2% gelatin (from porcupine skin) in PBS, for 30 minutes. 
The coverslips, with the cell-side facing down, were lowered onto a 1 :50 dilution of 
HPVl6118 E6 (CIP5) sc-480 mouse monoclonal IgG antibody (SantaCruz Biotechnology, 
California, USA) in blocking solution (0.2% gelatine in PBS) and incubated in a 
humidified chamber for 45 minutes at room temperature. The cells were then washed three 
times and a I :250 dilution of the Cy3-labelled affinity purified antibody to mouse IgG (H + 
L) (Xtra Serum Adsorbed, KPL, Maryland, USA) in blocking solution was added to the 
Ratl cells and a 1:400 dilution of the Alexa 488-labelled goat anti-mouse IgG antibody 
(Invitrogen, Ontario, Canada) was added to the EPC2 cells. The cells were incubated as 
for the primary antibody and kept in the dark for further steps. 
The cells were washed once in PBS for 5 minutes and 4' ,6-diamidino-2-phenylindole 
dihydrochloride (DAPI) (Sigma, Mannheim, Germany) was then added at a final 
concentration of 100 ng/ml in PBS and incubated for 5 minutes. The cells were washed, 
dipped in distilled water and mounted on slides using Mowiol® 4-88 Reagent (Calbiochem, 
California, USA). The slides were viewed using the Zeis Immunofluorescence 
microscope. HeLa cells were routinely included as a positive control and cells containing 
the pcDNA3 vector only were included as negative controls. Cells exposed only to the 
secondary antibody were included to check for any non-specific binding of the secondary 
antibody. 
2.2.14 Detection ofp53 by Western blot analysis 
p53 protein levels could not be determined in the transfected Rat I pools as no rat p53 
antibody was available. Protein was extracted from the transfected EPC2 pools, 8 to lO 











80-90% confluent and then placed on ice and washed three times using PBS. RIPA buffer 
containing Complete protease inhibitor cocktail (Roche, Mannheim, Germany) was added 
to the cells and scraped using a cell scraper. The protein lysates were sonicated for 
10 seconds and the samples were then centrifuged at 10 000 rpm for 10 minutes at 4°C. 
The supernatants were transferred to clean eppendorf tubes for quantification. 
2.2.14.1 Protein quantification 
The BCATM (Bicinchoninic Acid) Protein Assay Kit (Pierce, Illinois, USA) was used to 
quantify the protein lysates extracted from the transfected EPC2 pools. The protocol was 
followed as described by the manufacturer. Briefly, a standard curve was constructed 
using concentrations between 0 and 2000 ~g/ml of bovine serum albumin (BSA) diluted in 
RlPA buffer. The protein lysates were diluted in RlPA buffer to a I: 10 dilution and 25 ~l 
of test sample and the standard were pipetted into a Sero-WeI 96-well plate. RlP A buffer 
was used as the blank. 
A 200 ~l volume of BCA working solution (50 parts A: I part B) was added to each well 
and incubated at 37°C for 30 minutes. Reagent A (sodium carbonate, sodium bicarbonate, 
BCA detection reagent, sodium tartrate in 0.1 M NaOH) and Reagent B (4% CuS04.5H20) 
were supplied. After cooling to room temperature, the absorbance at 595 nm was recorded 
for each sample using a 96-well plate reader (EL800, BioTek Instruments, Winooski, 
USA). The concentration of the protein samples was extrapolated from the standard curve. 
2.2.14.2 Denaturing gel electrophoresis 
Protein lysates from cells were electrophoresed on 10% SDS polyacrylamide gels. The 
protein lysates (30 ~g) were added to Laemmli buffer, boiled for 10 minutes and loaded on 
a SDS-polyacrylamide gel. A protein molecular weight marker (PRN800 molecular 
weight marker, Amersham Biosciences, Buckinghamshire, UK) (Appendix A.2) was 
included for the determination of protein sizes. The polyacrylamide gel was prepared 
using 4% stacking gel on top of a 10% resolving gel. The gel tank apparatus (Bio-Rad 
Mini-Protean 3 Cell Assembly) was filled with running buffer and a voltage of 200 V was 











2.2.14.3 Electroblotting and immunodetection 
The resolved proteins were transferred onto a Hybond-ECL nitrocellulose membrane 
(Amersham Biosciences, Buckinghamshire, UK) for 1 hour at 100 V in Transfer Buffer. 
After transfer, the membrane was stained with Ponceau S for 5 minutes, destained in water 
for a few minutes until red protein bands could be visualised and a photocopied image was 
taken of the membrane as an indication of the loading. The membrane was further 
de stained using water and then finally rinsed with Tris-buffered saline containing 0.05% 
Tween-20 (TBS-T). After transfer, the gel was treated with fixing solution for 15 minutes, 
with shaking. Thereafter, the gel was incubated in Rapid Coomassie Blue for 15 minutes, 
with shaking, and then destained in 10% acetic acid, with shaking, until the protein bands 
were clearly visible. The gel was then dried on a Drygel Sr Slab Gel Dryer SE 1160, 
(Hoefer Scientific Instruments, San Francisco, USA) to check for loading. 
The nitrocellulose membrane containing the bound proteins was blocked in 5% non-fat 
milk powder for 1 hour, with shaking, to prevent non-specific binding of the antibodies to 
the membrane. Thereafter, a 1 :500 dilution of the monoclonal mouse anti-human p53 
protein clone DO-7 (DakoCytomation, Glostrup, Denmark) in TBS-T was added to the 
membrane and incubated overnight at 4°C with shaking. The membrane was washed 
3 times for 10 minutes each in TBS-T. AI: 1 000 dilution in TBS-T of the stabilised goat 
anti-mouse HRP-conjugated antibody (Pierce, Illinois, USA) was added and incubated at 
room temperature for 1 hour, with shaking. The membrane was sUbjected to three 
10 minute washes in TBS-T, to remove non-specific antibody binding. LumiGLO 
Reserve™ Chemiluminescent substrate kit (KPL, Maryland, USA) was used to visualise 
the protein bands as described by the manufacturer. The relative protein levels were 
analysed by densitometric scanning. 
2.2.15 Cell morphology analysis 
EPC2 and Ratl cells transfected with pcDNA3, pcDNA3-11E6 or pcDNA3-18E6 were 
plated on 22 rom diameter, sterile coverslips and incubated in normal growth medium at 
37°C in an incubator containing 5% CO2 until 70-80% confluent. The medium was 
removed from the cells and the cells were fixed using 4% PF A in PBS for 20 minutes at 











The coverslips were dipped in water and mounted on slides using Mowiol® 4-88 Reagent. 
The slides were then viewed using the Zeis microscope at 100X or 200X magnification. 
2.2.16 Cell proliferation analysis 
The MTT Cell Proliferation Kit (Roche, Mannheim, Germany) was used to determine cell 
growth rate. The assay involved plating 1 500 and 2 000 Ratl and EPC2 cells, 
respectively. Cells were plated in quadruplicate for every time point (i.e. 0, 1, 2, 3, 4 and 
5 days) in 96-well plates and medium was changed on day 3. After 3 hours at 37°C, 10 ).11 
of MTT reagent was added to each well. After at least 4 hours of incubation with MTT at 
37°C, 100 ).11 of solubilisation buffer was added to each well and incubated overnight at 
37°C in an incubator containing 5% C02. The following day, absorbance readings at 
595 nm were obtained to measure cell viability using a 96-well plate reader. This process 
was repeated for each time point. Changes observed in cell proliferation using the MIT 
assay were confirmed by counting the number of cells using a coulter counter. 
2.2.17 Cell cycle analysis 
Half a million transfected EPC2 or Rat 1 cells were plated in triplicate in 60 mm dishes and 
harvested when 80% confluent. To harvest the floating cells, the medium was removed 
and kept in a 12-ml tube. The adherent cells were harvested by rinsing twice with PBS 
(which was added to the medium in the 12-ml tube) and trypsinised using 1 ml of trypsin-
EDT A. The trypsin was neutralised using 1 ml DMEM containing FBS for the Rat 1 cells 
and soybean trypsin inhibitor for the EPC2 cells and the cells were added to the 12-ml 
tube. The harvested cells were pelleted by centrifugation at 1000 g for 5 minutes and 
resuspended in 2 ml medium, and counted using a haemocytometer. Cells were fixed by 
adding ice-cold ethanol (95%) to a final volume of 10 ml and left at -20°C for up to 
2 weeks. 
After fixation, the cells were centrifuged at 1000 g for 5 minutes, the supernatant removed 
and discarded. The pellet was rinsed twice using 1 ml PBS and on the second rinse, 
0.5-1.0 x 106 cells were aliquotted into a clean eppendorf. The cells were pelleted and 
200 ).11 of 50 ).1g/ml RNase A (Fermentas, Maryland, USA) diluted in PBS was added to the 











1 x 106 cells of propidium iodide stain solution was added to the cells 20 minutes before 
analysis on a Beckman Coulter F ACS-calibur flow cytometer (Buckinghamshire, UK). 
Ten thousand events were acquired on the flow cytometer after excluding doublets and 
debris. Subsequent data analysis was done using Flow Jo software. 
2.2.18 Peptide nucleic acid (PNA) studies 
The PNAs were designed and synthesised by Prof Lidia Boffa (1ST, Genoa, Italy). The 
sequence of the HPV18 E6 anti-gene peptide nucleic acid (PNAlS) was VKRKKKP-
aataaagatacagaac-NH2. A mutant PNA (PNAmut), VKRKKKP-tgaaaagtgaagata-NH2, was 
included in all the experiments to control for non-specific or cytotoxic effects. The PNAs 
were dissolved in sterile H20 and the pH was corrected to 7.0 using NaOH. HeLa was 
chosen as a model system as it is a known HPV 18-positive cervical cancer cell line 
(Boshart et ai., 1984). For all PNA experiments, the PNA1S or PNAmut were added at a 
final concentration of 10 IlM 
HeLa cells (500 000) were plated, in triplicate, in 60 mm dishes and allowed to settle 
overnight at 3rC in an incubator containing 5% C02. The next day, PNAIS or the PNAmut 
was added to the HeLa cells in triplicate. Untreated HeLa cells were also included as a 
control. Total RNA was extracted using QUlzol (QIAGEN, Hilden, Germany) 24 and 
48 hours after the addition of the PNAs. The cells were washed three times with PBS on 
ice and 1 ml of QUlzol was added per 60 mm dish. The cells were scraped using a cell 
scraper and stored at -80°C until further processing. 
For the RNA extraction, 200 III of chloroform was added and shaken vigorously by hand 
for 15 seconds. The samples were then incubated on ice for 10 minutes and centrifuged at 
8 000 rpm for 15 minutes at 4°C. The aqueous phase was added to a sterile tube and 500 III 
of isopropanol was added to the aqueous phase. This was incubated at -20°C overnight to 
precipitate the RNA. The samples were centrifuged at 8 000 rpm for 30 minutes at 4°C 
and the supernatant removed. One millitre of 75% ethanol was added the RNA pellet and 
gently resuspended. After centrifugation at 8 000 rpm for 30 minutes at 4°C the RNA 
pellet was air dried for about 10 minutes. The pellet was then dissolved in 20-30 III DEPC-
treated water and quantified as described in section 2.2.10. Two micrograms of total RNA 













The role of human papillomavirus (HPV) in the development of osee is poorly 
understood. It is therefore necessary to determine whether HPV E6 is a risk factor for the 
development of osee. This study looked at the effects of two HPV E6 proteins on 
cellular transformation, namely HPVl1 E6 and HPV 18 E6. HPV 11 E6, a low-risk HPV 
type, was chosen as it was found by Matsha et al. (2002) to be the most common HPV type 
in the South African osee patients. HPV18 E6 was chosen as an example of a high-risk 
HPV type that is commonly found in cervical cancer tumours (Snijders et at., 2006). The 
effects of the HPV E6 proteins were determined by, 1) introducing them into HPV-
negative cells and investigating the effects on cellular transformation, 2) knocking out 
HPV E6 in an HPV-positive cell line and determining the resultant effects. 
3.1 Human papillomavirus status of cultured cell lines 
Since the work to be done in this study depends on knowing the HPV status of the cells 
that are to be used, several cell lines were screened for the presence of HPV DNA. 
Genomic DNA was extracted from the cell lines and the serum albumin gene was 
amplified in order to determine the quality of the DNA. Figure 3.1 shows a representative 
picture of the amplification of human serum albumin. 
400 bp-+ 
300 bp -+ 
2 3 4 
+- 340 bp 
Figure 3.1: peR amplification of the human serum albumin gene. The DNA extracted from 
the cell lines was validated by the amplification of the human serum albumin gene as described in 
section 2.2.3 and resolved on a 1.5% agarose gel containing ethidium bromide. Lane 1: 1 Kb Plus 











After confinnation of the quality of the DNA for each of the cell lines, PCR was perfonned 
to amplify either the HPV L1 or E6 gene. It was necessary to check for both the HPV L1 
and E6 genes as the L1 gene may be disrupted when the viral DNA integrates into the host 
genome. Amplification of the HPV L1 gene involved nested PCR using the degenerate 
consensus primers, MY09 and MY 11 , and the non-degenerate GPS+ and GP6+ primers 
(section 2.2.3). None of the cell lines tested positive for HPV L1 except the positive 
controls, HeLa and CaSki. Amplification of the HPV E6 gene also revealed that none of 
the cell lines were positive for HPV E6 except HeLa and CaSki (Table 3.1). 
Table 3.1: HPV status of selected cell lines. DNA was extracted from the cell lines and PCR was 
perfonned to amplify either the HPV L 1 or E6 gene. 
Cell line Origin of cell line HPV HPV Reference 
Ll E6 
EPC2 Nonnal oesophageal epithelium - - Harada et al., 2003 
MCF12A Nonnal breast epithelium - - Paine et aI., 1992 
Ratl Rat fibroblast - - ATCC CRL-2210 
WHC01 OSCC - - Veal et al., 1989 
WHC03 OSCC - - Veal et al., 1989 
WHCOS OSCC - - Veal et al., 1989 
WHC06 OSCC - - Veal et al., 1989 
KYSE30 OSCC - - Shimada et aI. , 1992 
KYSE70 OSCC - - Shimada et aI. , 1992 
KYSE180 OSCC - - Shimada et aI., 1992 
KYSE520 OSCC - - Shimada et al., 1992 
HeLa Cervical SCC + + Boshart et al., 1984 
CaSki Cervical SCC + + Baker et al., 1987 
After the characterisation of the different cell lines with respect to their HPV status, three 
were chosen for transfection studies, i.e. MCF 12A, EPC2 and Ratl. 
3.2 Transfection of cell lines with HPV E6 
The HPV11 and HPV18 E6 genes were transfected into the EPC2, Rat1 and MCF12A cell 
lines to detennine whether the low- and high-risk HPV E6 proteins have different effects 
on cellular transfonnation. It was first necessary to detennine whether the pcDNA3 











3.2.1 Confirmation of the HPV E6 insert in the pcDNA3 constructs 
The pcDNA3 vector containing the appropriate HPV E6 insert was subjected to restriction 
enzyme analysis to confirm the presence of the insert. Digestion with the enzyme, AhaIII, 
resulted in the appropriate digestion products that allowed distinction between the HPV11 
and HPV18 E6 genes (Figure 3.2). The pcDNA3 vector generated fragments of 3365, 
1250, 692, 102 and 19 bp (of which only the three larger bands can be see on this gel), 
while the HPV11 E6 clone generated fragments of 3525, 1543, 692 and 19 bp and the 
HPV18 E6 clone generated fragments of 3695, 1397,692 and 19 bp. 
2 3 4 5 
Figure 3.2: Restriction enzyme analysis of the pcDNA3-HPV-E6 constructs. DNA was 
digested with AhaIII and resolved on a 1.4% agarose gel containing ethidium bromide as described 
in section 2.2.6. Lane 1: Marker X, lane 2: undigested pcDNA3 vector, lane 3: pcDNA3 digested 
with AhaIII, lane 4: pcDNA3-IIE6 digested with AhaIII, and lane 5: pcDNA3-18E6 digested with 
AhaIII . The 102 and 19 bp fragments could not be visualised as they were too small to be retained 
on the gel. 
After restriction digestion the inserts in the pcDNA3-11 E6 and pcDNA3-18E6 constructs 
were sequenced and the Nucleotide-Nucleotide Basic Local Alignment Search Tool 
(BLASTn) used to search the National Center for Biotechnology Information (NCBI) 
database to determine the identities of the gene. The sequencing alignments obtained 
confirmed the two HPV E6 genes present in the pcDNA3 vectors (Figure 3.3). After this 
confirmation, MCF12A, EPC2 and Ratl cells were transfected with either the empty vector 














1 111 1 1111 1 1111 11 111111 1 1 11 1 1 11111 1 11111 1 1 1 11 11111111 1 1 1 111 1 1 
11 E6: GGTTATATATAAACCAGCCCAAAAAATTAGCAGACGAGGCATTATGGAAAGTAAAGATGC 118 
CTCCACGTCTGCAACATCTATAGACCAGTTGTGCAAGACGTTTAATCTTTCTTTGCACAC 120 
1 1111 1 1 111111 1111 1 1 11111 1 1111 1 1 111 11 11 1 1111111 1 1 1 1 1 1 111 1 1111 
CTCCACGTCTGCAACATCTATAGACCAGTTGTGCAAGACGTTTAATCTTTCTTTGCACAC 178 
TCTGCAAATTCAGTGCGTGTTTTGCAGGAATGCACTGACCACCGCAGAGATATATGCATA 180 
11 1 11 11111 11 1 1111 11 1 1 1 1 1 1 11 1 1111111 1 1 11 1 1 1 11 1111 111 11 11 I 1111 
TCTGCAAATTCAGTGCGTGTTTTGCAGGAATGCACTGACCACCGCAGAGATATATGCATA 238 
TGCCTATAAGAACCTAAAGGTTGTGTGGCGAGACAACTTTCCCTTTGCAGCGTGTGCCTG 240 
11 1 1 1 11 1 1111111111 111 1 11 111111 1 1111111 1 1 1 11 1111 1 1 1 1 1 1111 11 1 1 
TGCCTATAAGAACCTAAAGGTTGTGTGGCGAGACAACTTTCCCTTTGCAGCGTGTGCCTG 298 
TTGCTTAGAACTGCAAGGGAAAATTAACCAATATAGACACTTTAATTATGCTGCATATGC 300 
111 1 1 1 111 111 1 1 I 1I 1 11 1 1 1 11 11 1 1111 1 II 1 1 111111 I I I I I I I I I I I I I I I I I 
TTGCTTAGAACTGCAAGGGAAAATTAACCAATATAGACACTTTAATTATGCTGCATATGC 358 
ACCTACAGTAGAAGAAGAAACCAATGAAGATATTTTAAAAGTGTTAATTCGTTGTTACCT 360 
11 1 1 11 1 11 1 1 1 11 11 1111 11 1 1 1 1 1 1111 1 1 111 11 1 1 1 1 1 11111 1 11 1 11 1 1 1 111 
ACCTACAGTAGAAGAAGAAACCAATGAAGATATTTTAAAAGTGTTAATTCGTTGTTACCT 418 
GTGTCACAAGCCGTTGTGTGAAATAGAAAAACTAAAGCACATATTGGGAAAGGCACGCTT 420 
111 1 1 11 111 111111111 1 11 11 1 11111 111 11111 11 11111 11 1111 1 111 1 11 11 
GTGTCACAAGCCGTTGTGTGAAATAGAAAAACTAAAGCACATATTGGGAAAGGCACGCTT 4 78 
CATAAAACTAAATAACCAGTGGAAGGGTCGTTGCTTACACTGCTGGACAACATGCATGGA 480 
I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I II 1 11 11 II I I I I III I I I I 
CATAAAACTAAATAACCAGTGGAAGGGTCGTTGCTTACACTGCTGGACAACATGCATGGA 538 
Insert:AAGATGTGAGAAACACACCACAATACTATGGCGCGCTTTGAGGATCCAACACGGCGACCC 60 
111 1 111111 11 1111 1 1 1 11 111 11 111 11111 111111 1 111 1 1 1 1111111 1 11 111 
18E6: AAGATGTGAGAAACACACCACAATACTATGGCGCGCTTTGAGGATCCAACACGGCGACCC 342 
TACAAGCTACCTGATCTGTGCACGGAACTGAACACTTCACTGCAAGACATAGAAATAACC 120 
111 11 111111 1 1111 1111 1111111 1 1 1 1 1 1111 11 11 1 111 11 111 11 1 1 1 1 11 11 1 
TACAAGCTACCTGATCTGTGCACGGAACTGAACACTTCACTGCAAGACATAGAAATAACC 402 
TGTGTATATTGCAAGACAGTATTGGAACTTACAGAGGTATTTGAATTTGCATTTAAAGAT 180 
11 1 1 1 11 1 1 1 1 11 1 1111 111 1 1111 1 1 1 11 111 11 1 1111111 1 1 1 1 1 1 11111 1 1 11 1 
TGTGTATATTGCAAGACAGTATTGGAACTTACAGAGGTATTTGAATTTGCATTTAAAGAT 462 
TTATTTGTGGTGTATAGAGACAGTATACCGCATGCTGCATGCCATAAATGTATAGATTTT 240 
1 11 1 11 1 1 11 1 1 11 111111 1 1 111111111 11 11111 111 1 11 1 11 1 1 1 1 1 111 I1 1 1 I 
TTATTTGTGGTGTATAGAGACAGTATACCGCATGCTGCATGCCATAAATGTATAGATTTT 52 2 
TATTCTAGAATTAGAGAATTAAGACATTATTCAGACTCTGTGTATGGAGACACATTGGAA 300 
11 1 1 1 I 11 1111 1 11111 1111 1 111 1 1 1111 1 111 11 11111 1 1 1 1111 1 1111111 11 
TATTCTAGAATTAGAGAATTAAGACATTATTCAGACTCTGTGTATGGAGACACATTGGAA 582 
AAACTAACTAACACTGGGTTATACAATTTATTAATAAGGTGCCTGCGGTGCCAGAAACCG 360 
11 11 1 111 11 1 1 11 1 1 111 1 1 1111 1 111 1 1 11 1 11 1 1 1 11 1 1 1 1111 11 1 1 1 11111 I I 
AAACTAACTAACACTGGGTTATACAATTTATTAATAAGGTGCCTGCGGTGCCAGAAACCG 642 
TTGAATCCAGCAGAAAAACTTAGACACCTTAATGAAAAACGACGATTTCACAACATAGCT 420 
I I I II I 1 1 1 1 I I I I I I I I II 11 1 I I I 1 111 I I I I I I I 1 11 1 1 I I I I I I I I 111111 I I I I 
TTGAATCCAGCAGAAAAACTTAGACACCTTAATGAAAAACGACGATTTCACAACATAGCT 702 
GGGCACTATAGAGGCCAGTGCCATTCGTGCTGCAACCGAGCACGACAGGAACGACTCCAA 480 
II I III I 1 111 I I I I I I I I I 1111 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
GGGCACTATAGAGGCCAGTGCCATTCGTGCTGCAACCGAGCACGACAGGAACGACTCCAA 762 
CGACGCAGAGAAACACAAGTATAATATTAAGTATGCATGGACCTAAGGCAACATTGCAAG 540 
I II 11 1 11 1 I I I I I I I I I I I I I I 1 I 11 I I I I I I I I I I 11111 I I I I I I I I 11111 I I I I I 
CGACGCAGAGAAACACAAGTATAATATTAAGTATGCATGGACCTAAGGCAACATTGCAAG 822 
Figure 3.3: Sequence alignment of the pcDNA3 HPV E6 inserts. The pcDNA3 inserts were 
sequenced as described in section 2.2.7 to confmn the presence of the correct HPV E6 gene. 
a) Sequence alignment of the HPVll E6 insert. The sequenced insert showed 100% (514/514) 
homology with the HPVll E6 gene (giI333026IgbIM14119.1IpPH11). b) Sequence alignment 
of the HPV18 E6 insert. The sequenced insert showed 100% (540/540) homology with the 











3.2.2 Transfection of the EPC2, Ratl and MCF12A cell lines 
Generally very low transfection efficiencies were observed for the EPC2, MCF12A and 
Ratl cell lines. Transfectin ™ Lipid Reagent gave better transfection efficiencies 
(compared to FuGENE®6 Transfection Reagent) for the MCF12A and Ratl cells. 
However, despite the better efficiency associated with it, Transfectin™ Lipid Reagent 
could not be used on the EPC2 cells as it was too toxic and killed all cells within 5 hours. 
Instead, FuGENE®6 Transfection Reagent was used to transfect the EPC2 cells. 
After transfection of the cells using the conditions outlined in Table 3.2, G418 was used to 
select for cells containing the pcDN A3 constructs. The concentration of G418 that caused 
substantial cell death within the first 4-5 days and killed all untransfected cells within 
2 weeks was chosen to select for successfully transfected cells. The G418 selection 
concentration for the EPC2, MCF12A and Ratl cells was 30, 350 and 400 Ilg/ml, 
respectively. Once the drug had killed all untransfected cells, the concentration of G418 
was reduced to a maintenance dose. The G418 maintenance dose for the EPC2, MCF12A 
and Ratl cells was 30, 150 and 200 Ilg/ml, respectively. 
Table 3.2: Transfection of EPC2, MCF12A and Rat! cells. Different transfection reagents and 
conditions were tested on the cell lines to optimise for transfection efficiency. This table shows the 
conditions used. 
Dish Volume of Amount of Incubation time 
Cell line Reagent used size reagent plasmid before adding 
(mm) added J1-11) added (rtgl G418 (bours) 
EPC2 FuGENEQY6 60 14 2.21 96 
MCF12A Transfectin Ti\1 35 1 0.5 48 
Ratl Transfectin ™ 100 6 3 48 
After G418 selection, pools of transfected cells were used for further analysis since 
isolation of individual cells proved difficult for the epithelial cells. Three pools of cells 
containing the pcDNA3 vector, 7 pools of cells containing pcDNA3-11 E6, and 8 pools of 











3.2.3 Confirmation of the presence of HPV E6 genes in selected pools 
Prior to performing the subsequent experiments on the transfected pools, it was important 
to confirm the presence of the HPV E6 genes in each of the pools. DNA was extracted and 
peR amplification of the HPV E6 genes confirmed their presence. In all cases, the quality 
of the DNA was checked by amplifying a small fragment of either the human or rat serum 
albumin gene. Figure 3.4 shows that the DNA extracted from the pools of each cell line 
was of good quality. 
a) 
b) 
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Figure 3.4: Integrity of extracted DNA. Genomic DNA extracted from the transfected cells was 
validated by the amplification of the serum albumin gene as described in section 2.2.3 and the 
products were separated on 2% agarose gel and visualised by staining with ethidium bromide. 
a) PCR amplification of the rat serum albumin gene from extracted DNA. Lane 1: 50 bp DNA 
ladder, lane 2: Ratl-IIE6 pool 1, lane 3: RatI-IIE6 pool 2, lane 4: Ratl-IIE6 pool 3, lane 5: RatI-
18E6 pool 1, lane 6: RatI-I8E6 pool 2, lane 7: RatI-I8E6 pool 3, lane 8: Ratl-pcDNA3, lane 9: 
Rat 1 , and lane 10: no template control. b) PCR amplification of the human serum albumin gene 
from extracted DNA. Lane 1: 50 bp DNA ladder, lane 2: EPC2, lane 3: EPC2-pcDNA3, lane 4: 
EPC2-IIE6 pool 1, lane 5: EPC2-IIE6 pool 2, lane 6: EPC2-18E6 pool 1, lane 7: EPC2-18E6 pool 
2, lane 8: EPC-I8E6 pool 3, lane 9: MCFI2A, lane 10: MCFI2A-pcDNA3, lane 11: MCFI2-IIE6 
pool 1, lane 12: MCFI2A-IIE6 pool 2, lane 13: MCFI2A-I8E6 pool 1, lane 14: MCFI2A-I8E6 













The DNA from each pool was used to amplify HPV11 or HPV18 E6 in all the transfected 
cells (Figure 3.5 and 3.6). For Rat1, pools 1,2 and 3 transfected with the pcDNA3-11E6 
construct were all positive for the HPVl1 E6 gene (Figure 3.5a). Similarly, pools 1, 2 
and 3 transfected with the pcDNA3-18E6 construct were all positive for the HPV18 E6 
gene (Figure 3.5b) with no cross amplification between HPVll and 18 E6 (compare lanes 
2-4 with 5-7 in Figure 3.5 a and b). EPC2-11 E6 pool 1 was positive for HPV11 E6 but 
pool 2 was negative (Figure 3.6a). Neither of the MCFI2A-ll E6 pools contained the 
HPVl1 E6 gene. All three of the EPC2-18E6 pools were positive for the HPV18 E6 gene, 
however MCFI2A-18E6 pool 1 was positive for the HPV18E6 gene but pool 2 was not 
(Figure 3.6b). The MCF12A transfected cells were discontinued from further analysis as 
all the transfected cells, including the cells containing pcDNA3, became spindly in shape 
and stopped growing. The EPC2-11 E6 pool 2 was also discontinued from the study as it 
did not contain the HPVl1 E6 gene. 
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Figure 3.5: Amplification of HPV E6 genes in Ratl transfected cells. The presence of the 
HPV 11 and 18 E6 genes was validated by the amplification of a 112 bp region of the HPV 11 E6 
gene and a 423 bp region of the HPV 18 E6 gene from DNA extracted from the pools as described 
in section 2.2.3. The peR products were resolved on 2% (HPV11 E6) and 1.5% (HPV18 E6) 
agarose gel, and visualised by staining with ethidium bromide. a) HPVll E6 peR. Lane 1: 
Marker VIII, lane 2: Ratl-11E6 pool 1, lane3: Ratl-11E6 pool 2, lane 4: Ratl-11E6 pool 3, lane 5: 
Ratl-18E6 pool 1, lane 6: Ratl-18E6 pool 2, lane 7: Ratl-18E6 pool 3, lane 8: Rat1-pcDNA3, 
lane 9: Rat1, and lane 10: no template control. b) HPV18 E6 peR. Lane 1: 50 bp DNA ladder, 
lane 2: Ratl-11E6 pool 1, lane3: Ratl-11E6 pool 2, lane 4: Rat1-11E6 pool 3, lane 5: Ratl-18E6 
pool 1, lane 6: Ratl-18E6 pool 2, lane 7: Ratl-18E6 pool 3, lane 8: Rat1-pcDNA3, lane 9: Rat1, 
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Figure 3.6: Amplification of HPV E6 genes in transfected EPC2 and MCF12A cells. The 
presence of the HPV 11 and 18 E6 genes was validated by the amplification of a 112 bp region of 
the HPVll E6 gene and a 423 bp region of the HPV18 E6 gene from DNA extracted from the 
pools as described in section 2.2.3. The PCR products were resolved on 2% (HPVll E6) and 1.5% 
(HPV 18 E6) agarose gel and visualised by staining with ethidium bromide. a) HPVll E6 PCR. 
Lane 1: Marker VIII, lane 2: EPC2, lane 3: EPC2-pcDNA3, lane 4: EPC2-11E6 pool 1, lane 5: 
EPC2-11E6 pool 2, lane 6: EPC2-18E6 pool 1, lane 7: EPC2-18E6 pool 2, lane 8: EPC-18E6 
pool 3, lane 9: MCFI2A DNA, lane 10: MCFI2A-pcDNA3, lane 11: MCF12-11E6 pool 1, lane 12: 
MCFI2A-llE6 pool 2, lane 13: MCFI2A-18E6 pool I, lane 14: MCFI2A-18E6 pool 2, and 
lane 15: no template control. b) HPV18 E6 PCR. Lane 2: EPC2, lane 3: EPC2-pcDNA3, lane 4: 
EPC2-11E6 pool, lane 5: EPC2-11E6 pool 2, lane 6: EPC2-18E6 pool 1, lane 7: EPC2-18E6 
pool 2, lane 8: EPC-18E6 pool 3, lane 9: MCFI2A, lane 10: MCFI2A-pcDNA3, lane 11: MCFI2-
l1E6 pool 1, lane 12: MCFI2A-I1E6 pool2, lane 13: MCFI2A-18E6 pool 1, lane 14: MCFI2A-
18E6 pool 2, lane 15 : HeLa, and lane 16: no template control. 
3.2.4 Transcription of the HPV E6 genes in the transfected pools 
After confinning the presence of the HPV E6 genes in the transfected pools, it was 
necessary to investigate whether the genes were transcribed and translated before 
investigating any effects on the cell. Figure 3.7 shows an example of the integrity of the 
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Figure 3.7: Integrity of extracted total RNA. Total RNA was extracted from all the transfected 
pools and 1 flg of RNA from each pool was electrophoresed on a formaldehyde-containing agarose 
gel to determine whether the RNA was intact as described in section 2.2.10. Lanes 1-3: RNA from 
Ratl-llE6 pool 1, lanes 4-6: RNA from Ratl-llE6 pool 2 and lanes 7-9: RNA extracted from 
Ratl-llE6 pool 3. 
After confinning the integrity of the extracted RNA, cDNA was synthesised for 
quantitative RT-PCR analysis. Relative standard curves were constructed to detennine the 
efficiencies of the different amplification reactions using either human GAPDH, rat 
GAPDH, HPV11 E6 or HPV18 E6 specific primers. Different efficiencies were obtained 
for the reactions. The amplification reaction using the HPV 18 E6 primers had the highest 
efficiency (1.96), followed by the reaction containing the HPV 11 E6 primers (1.85). The 
efficiencies of the reactions containing the rat and human GAPDH primers were lower at 
1.82 and 1.78, respectively. It was necessary to calculate the efficiencies in order to use 
the nonnalisation with calibrator method (section 2.2.12) for analysing the relative mRNA 
levels in the transfected cells. 
The relative HPV11 and HPV18 E6 mRNA levels were calculated for the different 
transfected pools using either rat GAPDH (for the Ratl pools) or human GAPDH (for the 
EPC2 pools) as the nonnaliser. The three Ratl-11E6 pools showed different HPV11 E6 
mRNA levels with pool 1 containing the lowest compared to pools 2 and 3 (Figure 3.8a). 
Pool 3 had about 6-fold higher HPV11 E6 mRNA compared to pool 1. A smaller 
difference in the HPV E6 mRNA levels was observed in the three Ratl-18E6 pools with 
pool 3 having slightly lower HPV18 E6 mRNA levels than pools 1 and 2 (Figure 3.8b). 
For the EPC2 pools, there was only one pool obtained containing the HPV11 E6 gene and 
therefore RT-PCR without quantification was perfonned on that pool. The HPV11 E6 
gene was transcribed within the pool (Figure 3.9a). In the EPC2-18E6 pools, pool 3 had 
about 2-fold higher HPV18 E6 mRNA levels than pool 1 (Figure 3.9b). It was not possible 











past passage 7. This pool was therefore discontinued from further analysis. On the whole, 
the HPVll and HPV18 E6 mRNA levels in the EPC2 and Ratl transfected cells were 
comparable. However, it should be noted that HPVll E6 was transcribed at substantially 
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Figure 3.9: HPV E6 mRNA levels in EPC2 transfected cells. Total RNA was extracted from 
the EPC2 pools and RT-PCR or quantitative RT-PCR was performed as described in section 
2.2.12. Relative mRNA levels were determined and the lowest expressing pool was assigned a 
value of 1. a) RT-PCR on EPC2-11E6 pool 1. Lane 1: 50 bp DNA ladder, lane 2: no-reverse 
transcriptase control to check for DNA contamination, and lane 3: amplification of cDNA from 
EPC2-11E6 pool 1. b) Relative HPV18 E6 mRNA levels in two EPC2-18E6 pools. Each bar 
represents the mean of triplicate samples. Error bars represent standard deviation. ** p< 0.01 











It is known that a proportion of the HPV18 E6 mRNA transcripts in HeLa cells are spliced 
giving rise to a smaller E6 protein (Ingaki et aI., 1988). This was similarly found to be the 
case in the HPV18-E6-transfected EPC2 and Ratl cells (Figure 3.10). The spliced HPV18 
E6 mRNA seemed to be more abundant than the unspliced mRNA. 
500 bp --. 
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Figure 3.10: Splicing of HPV18 E6 mRNA. RNA was extracted from the transfected cells and 
PCR, using primers that amplify both full length (resulting in a 423 bp product) and alternatively 
spliced (resulting in a 250 bp product) HPV 18 E6 mRNA, was performed as described in section 
2.2.12. Lane 1: 50 bp DNA ladder. Lanes 2, 4 and 6: Amplification of DNA from Ratl, EPC2 and 
HeLa cells, respectively. Lanes 3, 5 and 7: Amplification of cDNA from Rat 1, EPC2 and HeLa 
cells, respectively. Lane 8: no template control. 
3.2.5 Detection of HPV E6 protein in the transfected cells 
After confirming that the HPV E6 genes were transcribed, it was necessary to confinn that 
the mRNA was translated into protein in the Ratl and EPC2 pools. This was done using 
immunofluorescence. There is no commercially available antibody to detect HPVll E6 
expression therefore the assays were perfonned for HPV18 E6 only. Figure 3.11 shows 
the images that were captured under the fluorescent microscope confirming the presence of 
the HPV18 E6 protein in the Ratl-18E6 and EPC2-18E6 pools. 
All cells in the Ratl-18E6 and EPC-18E6 pools expressed HPV18 E6. In some cells, 
HPV18 E6 was observed only in the cytoplasm and in others it was observed in both 
cytoplasm and to a lesser extent in the nucleus (Figure 3.lla). The Ratl-pcDNA3 pool 
gave no signal in the Cy3 channel indicating that the labelling is specific for HPVl8 E6. 
Similarly, the EPC2-pcDNA3 pool gave no signal indicating that the green signal is 
specific for HPV18 E6 expression (Figure 3.11b). For the EPC2-18E6 pools, staining was 

































Figure 3.11: Localisation of the HPV18 E6 protein in the transfected pools. Cells were 
cultured on sterile coverslips, fixed and probed with an antibody to detect for HPV 18 E6 protein as 
described in section 2.2.13. DAPI was used for nuclear staining and images were viewed at a 
magnification of 200 times. a) Transfected Ratl cells. The Cy3 channel was used to detect for 
HPV18 E6 expression. b) Transfected EPC2 cells. The Alexa 488 channel was used to detect for 












3.3 The effects of HPV E6 on the transfected cells 
After confinning expression of the HPV E6 gene, the next step was to investigate the effect 
of these proteins on the transfected cells. HPV E6 is known to interact with the tumour 
suppressor, p53, thus it was necessary to check the effects of HPV E6 on p53 protein 
levels. 
3.3.1 Effect of HPV E6 on p53 levels 
Western blot analysis was perfonned on whole cell lysates prepared from the transfected 
EPC2 cells. This could not be perfonned on the transfected Rat1 cells as the human p53 
antibody does not cross-react with rat p53. Figure 3.12 shows that p53 levels were 
significantly decreased in the celIs producing HPV18 E6 protein compared to the levels in 
the ceI1s containing the pcDNA3 vector only (Figure 3.12a). The HPV18 E6 proteins 
resulted in a 45-65% reduction in the p53 levels in the EPC2 cells (Figure 3.12b). 
However, HPV11 E6 did not affect the p53 levels as there were no differences between 
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Figure 3.12: p53 protein levels in transfected EPC2 cells. p53 protein levels were determined 
using western blot analysis as described in section 2.2.14. Tubulin was included to correct for 
loading. a) Autoradiograph showing the p53 and tubulin protein levels in the different 
samples. Lane 1: EPC2-pcDNA3, lane 2: EPC2-18E6 pool 1, lane 3: EPC2-18E6 pool 3, and 
lane 4: EPC2-11E6 pool 1. b) and c); the relative p53 protein levels, analysed using 
densitometry, in the EPC2 cells containing HPV 18 E6 or 11 E6, respectively. p53 protein level in 












3.3.2 Effect of HPV E6 on cell morphology 
The transfected EPC2 and Ratl cells were monitored for any morphological changes that 
might occur in response to expression of the HPVll or HPV18 E6 genes. No changes in 
morphology were observed in the transfected Ratl or EPC2 cells. Figure 3.13 shows a 
representative picture of the morphologies of the different pools. 
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Figure 3.13: Morphology of transfected cells. Cells were plated on sterile covers lips, fixed and 
viewed under a microscope to investigate any morphological changes as described in section 
2.2.15 . a) Morphology of the EPC2 cells transfected with pcDNA3, pcDNA3-11E6 or pcDNA3-
18E6. b) Morphology of the Ratl cells transfected with pcDNA3, pcDNA3-11E6 or pcDNA3-
18E6. 
3.3.3 Effect of HPV E6 on cell growth rate 
The growth rate of the transfected EPC2 and Ratl cells was investigated . Figure 3.14 
a and b show the growth rates of the transfected Ratl cells. All the Ratl-Il E6 and 



















































pool 3 which showed a significantly slower growth rate of almost 70% after 4 days. This 
result was confirmed by counting the number of cells over a period of 5 days using a 
coulter counter and a 50% decrease in the growth rate of the Ratl-II E6 pool 3 was seen 
(Figure 3.15). Rat1-11E6 pool 3 also had the highest HPV1I E6 mRNA levels 
(Figure 3.8a). The growth rate of the EPC2 cells remained unaltered in the presence of 
either the HPV11 or HPV18 E6 protein (Figure 3.14 c and d) . 
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Figure 3.14: Growth rates of HPV E6 transfected cells. The growth rate of the transfected cells 
was determined using the MIT Cell Proliferation assay as described in section 2.2.16 . a) Growth 
rate of the three Ratl-llE6 pools compared to the growth rate of the Ratl-pcDNA3 cells. 
b) Growth rate of the three Ratl-18E6 pools compared to the growth rate of the Ratl-pcDNA3 
cells. c) Growth rate of the EPC2-11E6 pool 1 compared to the growth rate of EPC2-pcDNA3 
cells. d) Growth rate of the two EPC2-18E6 pools compared to the growth rate of EPC2-
pcDNA3 cells . Each point represents the mean of four wells, with each experiment done at least 
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Figure 3.15: Confirmation of the growth rate of the Ratl-llE6 pools. The growth rate of the 
three Ratl-ll E6 pools compared to the growth rate of the Ratl-pcDNA3 cells was investigated 
using a coulter counter to count the number of cells over time. Each point represents the mean of 
three wells. The error bars indicate standard deviations. 
3.3.4 Effect of HPV E6 on cell cycle progression 
To further investigate the effects of HPV E6, cell cycle analysis was performed. Figure 
3.16 a-c shows the cell cycle distribution profiles of Ratl transfected cells. Ratl-l1 E6 
pool 3, the slower growing pool with the highest HPVll E6 mRNA levels, had a 
substantially altered cell cycle profile compared to the Ratl-pcDNA3 cells. An increase in 
the percentage of cells in G2 and a 4-fold increase in the percentage of cells with DNA 
content greater than 4N was observed (i.e. there was an emergence of a small aneuploid 
population of cells indicated by the arrow in Figure 3.16a). The cell cycle distribution 
profiles of the Ratl-llE6 pool 1 and 2 were the same as those of the Ratl-pcDNA3 cells. 
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Figure 3.16: Cell cycle analysis of HPV E6 transfected cells. Cells were harvested, 
penneabilised and the DNA stained with propidium iodide to determine the percentage of cells in 
each phase of the cell cycle (section 2.2.17). a) Cell cycle distribution profiles for Ratl-pcDNA3, 
Ratl-llE6 pool 3 and a representative profile for the Ratl-18E6 transfectants. b) and c) show 
graphical representations of the distributions of the cell cycle in the Rat 1-11 E6 and 18E6 pools, 
respectively. d) Cell cycle distribution profiles obtained for EPC2-pcDNA3, EPC2-11E6 and 
EPC2-18E6. e) and f) show graphical representations of the distributions of the cell cycle in the 
EPC2-11 E6 and 18E6 pools, respectively. Each bar represents the mean of triplicate samples, with 
each experiment done at least twice. The error bars indicate standard deviation. * p< 0.05, 











There was no difference in the cell cycle distribution profiles of the three Ratl-18E6 pools 
(Figure 3.16c). A significant increase in the percentage of cells in Gland a slight decrease 
in the percentage of cells in G2, compared to Rat1-pcDNA3 cells, was observed for all 
three pools. There was no increase in the percentage of cells with DNA content greater 
than G2 compared to what was observed in the Rat1-pcDNA3 cells. For the transfected 
EPC2 cells (Figure 3.16 d-f), there was no change in the cell cycle profiles for the pools 
containing HPV11 or HPV18 E6, compared to the EPC2-pcDNA3 cells. 
3.4 HPV E6 knockout using peptide nucleic acids 
The aim of this study was to investigate whether down regulating HPV18 E6 expression in 
cells already expressing this gene had any effect on the transformed phenotype. All the 
oesophageal cancer cell lines tested in our laboratory were negative for HPV DNA 
(Table 3.1), thus HeLa (a known HPV18-positive cell line) was used as a model system. 
The experiments involved the use of peptide nucleic acids (PNAs) that were designed to 
target and down regulate expression of the HPV 18 E6 gene. 
3.4.1 HPV18 E6 mRNA levels in PNA-treated cells 
Quantitative RT-PCR was used to determine the effects of the HPV18 E6 anti-gene PNA 
(PNA1S) on HPV18 mRNA levels in HeLa cells. A non-specific, mutant PNA (PNAmut) 
designed not to bind to HPV18 E6 was included to control for non-specific or cytotoxic 
effects. Total RNA was extracted from PNAls-treated, PNAmut-treated and untreated cells. 
The quality and integrity of extracted RNA was tested as described earlier and Figure 3.17 
shows an agarose gel of total RNA. 
RNA was isolated 24 and 48 hours after PNA treatment and cDNA synthesis and qRT-
PCR were performed to determine relative HPV18 E6 mRNA levels. PNAls was effective 
in decreasing the relative HPV18 E6 mRNA levels in HeLa cells by approximately 20%, 
compared to untreated cells, 24 hours after treatment (Figure 3.18a). A larger decrease 
(35%) was detected 48 hours after treatment (Figure 3 .18b). However, the mutant also 
affected the HPV18 mRNA levels and caused a larger decrease than the PNAls at both 
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Figure 3.17: Integrity of extracted RNA. Total RNA was extracted from PNA-treated cells and 
2 )lg of RNA from each sample was electrophoresed on a formaldehyde-containing agarose gel to 
detennine whether the RNA was intact as described in section 2.2.10. Lanes 1-3: RNA from 
untreated HeLa cells, lanes 4-6: R]\TA from HeLa cells treated with PNAmu( for 24 hours, and 
lanes 7-9: RNA extracted from HeLa cells treated with PNA I8 for 24 hours. 
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Figure 3.18: Relative HPV18 mRNA levels in PNA-treated HeLa cells. Cells were treated with 
PNAI8, PNAmu( or left W1treated and qRT-PCR was performed as described in section 2.2 .12. The 
HPVl8 E6 mRNA levels were detennined and plotted relative to W1treated HeLa cells that were 
assigned a value of I. a) Relative HPV18 mRNA levels 24 hours after treatment, b) relative 
HPV18 E6 mRNA levels 48 hours after treatment. Each point represents the mean of triplicate 
samples, showing standard deviation. This result is representative of four independent 
experiments. * p<O.05, **p<O.Ol compared to W1treated. 
3.4.2 Cell proliferation in PNA-treated cells 
Cell proliferation was investigated to detennine whether the decrease in HPV18 E6 mRNA 
levels observed in the presence of PNA resulted in decreased cell growth. Figure 3.19 
shows the growth of the untreated and PNA-treated HeLa cells with a decrease in cell 
growth observed in the presence of PNA 1S . Unfortunately, PNAmut also appeared to cause 
a decrease in cell growth. A 40-45% decrease in the growth rate of the cells was observed 





























0 2 3 4 
Time (days) 
Figure 3.19: Growth rate of HeLa cells after PNA treatment. PNA I8 and PNAmut were added to 
BeLa cells and a MIT cell proliferation assay was performed as described in section 2.2.18. Each 
point represents the mean of 4 wells showing the standard deviation. This is representative of three 
independent experiments. 
The observed decreased cell growth rates in both PNAlS- and PNAmu[-treated cells pointed 
to the possibility of general toxicity to the cells. In order to confinn this, the PNA 
experiment was repeated in an HPV-negative cell line, WHCOL Figure 3.20 shows that 
both the PNA l8 and PNAmu[ decreased the growth rate of the WHCOI cells. This confinns 
that the PNAs are generally cytotoxic when added at a final concentration of I 0 ~M. The 
decrease in cell growth seen in Figure 3.19 could therefore not be attributed to a decrease 
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Figure 3.20 Growth rate of WHCOI cells after treatment with PNA. PNAI8 and PNAmul were 
added to WHeOI cells (known to be HPV negative) and the MIT cell proliferation assay was 













Discussion and Conclusions 
4.1 Discussion 
Oesophageal squamous cell carcinoma is a concern worldwide and particularly in South 
Africa. The cause of OSCC is not known, but different risk factors are associated with 
OSCC, such as excessive alcohol consumption and tobacco smoking (Wu et al., 2006; 
Pacella-Norman et al., 2002; Syrjanen, 2002; Pinto et al., 2003), nutritional deficiencies 
(Sur and Cooper, 1998), genetic polymorphisms (Pinto et al., 2003; Lin et al., 1998; 
Dandara et al., 2005; 2006) and infection with the human papillomavirus (Matsha et al., 
2002; Farhadi et al., 2005; Katiyar et al., 2005; Furihata et al., 1993, Chang et al., 1990; 
1992; 2000). The association between HPV and OSCC is poorly understood and has been 
the focus of this study. 
Human papillomaviruses are categorised into high- and low-risk types depending on their 
association with causing cervical cancer (Motoyama et al., 2004). The so called "low-risk" 
HPV11 was found to be the most common type in South African OSCC patients (Matsha 
et al., 2002). It is therefore necessary to determine whether HPVll is a risk factor for the 
development of OSCC or merely a bystander. HPV18 was not detected in the cohort of 
OSCC patients in the study by Masha et al. (2002), but this type has been identified in 
oesophageal tumour cells in other studies (Cooper et al., 1995; Lavergne and de Villiers, 
1999). In this project, the role of HPV E6 proteins in OSCC was investigated by 
evaluating the effects of either introducing HPV E6 genes into HPV -negative cell lines or 
by knocking out the expression of E6 genes in an HPV -positive cell line. 
4.1.1 Introducing HPV E6 genes into HPV-negative cell lines 
Two different HPV E6 genes, HPV 11 and HPV 18 E6, were transfected into cells to 
determine whether these proteins playa role in the development of OSCC or are merely 
spectators. HPV 11 E6, a low-risk HPV type, was chosen as this was the most common 
type found in South African OSCC patients and HPV18 E6 was chosen as a reference to 
compare with a high-risk type. EPC2 and MCF12A cells were selected as examples of 











included as they are routinely used in transfection studies and also because several studies 
have looked at the effects of HPV proteins in fibroblasts (Malanchi et at., 2004; Bedell et 
at., 1987). A comparative analysis between different cell types may therefore be useful. 
In the transfection studies, three of the MCF12A pools and one of the EPC2 pools 
unfortunately did not contain the HPV E6 gene. Lack of the HPV E6 gene in the EPC2 
pool could have been due to the very low 0418 concentration used to select for transfected 
EPC2 cells (30 !lg/ml). This might have allowed for the emergence of spontaneously 
resistant cells. Use of higher 0418 concentrations to select for successfully transfected 
EPC2 cells were attempted (between 50 to 100 !lg/ml) but always resulted in complete cell 
death of the transfected cells. The 0418 concentration used to select for transfected 
MCF12A cells was much higher (450 !lg/ml). However, we speculated that the transfected 
MCF12A cells lacking the HPV E6 gene may have come about due to excision of the E6 
gene, but maintaining the neomycin resistance gene. Alternatively, in both the transfected 
EPC2 and MCF12A cells lacking the HPV E6 genes, the gene may have integrated in a 
transcriptionally inactive portion of the genome. All transfected pools lacking the HPV E6 
gene were excluded from the study. 
In the pools that contained the HPV 11 or HPV 18 E6 genes, transcription of the genes 
occurred at varying levels. This may have been due to the copy number of pcDNA3 
constructs present in each of the pools or the sites of integration of the HPV E6 genes 
within the genome. It was not possible to detect HPV E6 protein expression by western 
blot analysis in this study. There were no commercially available antibodies to detect 
HPV 11 E6 and therefore it was not possible to confirm that the HPV 11 E6 protein was 
produced in the EPC2-11 E6 and Ratl-11 E6 pools. Attempts to produce polyclonal 
antibodies against HPV 11 E6 and HPV 18 E6 proteins fused to glutathione-S-transferase 
tags in our laboratory were unsuccessful. 
It has been observed that HPV E6 proteins are expressed at very low levels making them 
difficult to detect. In fact, in many studies that look at HPV E6 proteins, they only show 
E6 mRNA using RT-PCR or Nothern blot analysis (Homer et al., 2004; Slebos et at., 
1995) because of the known difficulties in detecting HPV E6 proteins. Other studies add a 
green fluorescent tag or a HA (hemagglutinin) or Flag tag onto the HPV E6 proteins to aid 











have been added to the HPV E6 proteins in this study. This would also have allowed the 
detection of HPV 11 E6 expression without the use of specific HPV 11 E6 antibodies. 
The monoclonal antibody to detect HPV 18 E6 expression within the HPVI8-E6-positive 
cells did not work well for western blot analysis, but gave good results when used in 
immunofluorescence. Immunofluorescence confirmed that all cells in the Rat 1-18E6 and 
EPC2-18E6 pools expressed the HPV 18 E6 protein, and that it was localised to the 
cytoplasm of some cells and the cytoplasm and nucleus (to a lesser extent) of other cells. 
This observation is in agreement with what is reported in the literature (Vaeteewoottachern 
et al., 2005; Li et al., 2005). 
We observed alternatively spliced HPV18 E6 mRNA in cells transfected with HPV18 E6. 
The alternatively spliced HPV18 E6 mRNA was observed in the three Ratl-18E6 and three 
EPC2-18E6 pools, indicating that the splicing event was not cell specific. Our observation 
is in agreement with that of Ingaki et al. (1988) who showed that HPV18 E6 transcripts 
present in HeLa cells were alternatively spliced, leading to the production of a smaller E6 
protein, named E6*. The HPV 18 E6* protein is 6.5 kDa in size instead of 18.9 kDa 
because the splicing causes a change in the reading frame leading to the introduction of a 
premature stop codon (Schneider-Gadicke et aI., 1988). 
Our results appear to show that the alternatively spliced HPV 18 E6 mRNA was in 
abundance (compared to unspliced HPV18 E6 mRNA), confirming the findings in other 
studies that the full le gth HPV E6 transcripts are in extremely low abundance (Zheng and 
Baker, 2006; Smotkin and Wettstein, 1986). This could help to explain why the HPV 18 
E6 protein was difficult to detect in this study. It has been shown that the E6* proteins 
negatively regulate the expression of the active, full-length E6 proteins therefore 
contributing to low HPV E6 protein levels (Sedrnan et ai., 1991). Splicing of HPV E6 
mRNA has also been observed for HPV16 E6, another high-risk HPV type, but no study 
has shown this phenomenon in the low-risk HPV types, including HPV 11 E6 (Stacey et 
aI., 1995; Sedman et ai., 1991; Schneider-Gadicke et al., 1988). 
The observation in our study that HPV18 E6 resulted in decreased p53 protein levels, 











HPV E6 proteins (e.g. HPV 18 E6) form a trimeric complex by binding p53 and the E6-
associated protein (E6AP) (Zanier et aI., 2005; Wemess et at., 1990). This complex 
formation increases the rate of degradation of p53, which is associated with decreased p53 
protein levels in HPV -infected cells. In contrast, the low-risk HPV E6 proteins (e.g. 
HPV11 E6) are unable to bind E6AP and p53 and therefore do not result in decreased p53 
levels (Zanier et at., 2005; Malanchi et at., 2004; Slebos et at., 1995). The decreased p53 
levels in transfected EPC2 cells indicated that the HPV 18 E6 protein was functionally 
active. The difference in the effects of HPV 11 and HPV 18 E6 proteins show that the low-
and high-risk HPV E6 proteins possibly act via different pathways. It would be interesting 
for future work to identify the different pathways altered by the low- and high-risk HPV 
E6 proteins using microarray analysis. 
We also investigated the effects of HPVll and HPV18 E6 proteins on cell growth. 
Previous studies have shown that both the high- and low-risk HPV E6 proteins are 
associated with increased growth rates of cells (Malachi et at., 2004; You et at., 2002). In 
contrast, most of the transfected Rat1 and EPC2 pools did not show any change in overall 
growth rate, except for one of the Ratl-l1E6 pools. Ratl-11E6 pool 3, the pool with 
highest HPVll E6 mRNA levels, grew significantly slower than the cells containing the 
pcDNA3 vector only. This pool also had a markedly different cell cycle distribution 
profile than the cells containing pcDNA3. There was an emergence of a small aneuploid 
population and an increase in the proportion of cells in 02. Some cells in this slower-
growing pool may be cycling between 4N and 8N. Some of the cells were probably 
undergoing crisis and therefore growing slower. More detailed analysis needs to be 
performed to confirm the mechanisms that result in an increase in the DNA content in the 
cells. 
An increase in the percentage of cells with DNA content greater than 02 was not observed 
in the EPC2-11 E6 pool. This may be because the expression levels of HPV11 E6 were 
lower than that of the slower-growing Rat 1-11 E6 pool. There was only one pool of EPC2 
cells containing the HPV 11 E6 gene so this result would need to be confirmed by 
generating several pools of transfectants. There was no increase in the percentage of cells 
with DNA content greater than 02 observed in the HPV 18 E6-transfected cells, as was 
observed in HPVl1 E6 transfected Rat1 cells. In the literature, there are contradictory 











E7 expression is required. The difference seems to depend on the different growth 
conditions used (Patel et ai., 2004; Schaeffer et aI., 2004). It is possible that no change in 
the cell cycle and growth rate of the cells was observed in this study due of the lack of 
HPV E7 expression. 
Some studies have reported that HPV E6 proteins affect cell morphology (You et aI., 2002; 
Malanchi et aI., 2004), however no change in the morphology of the transfected EPC2 or 
Ratl cells was observed. A study by Bedell et al. (1987) showed distinct morphological 
changes in Ratl cells expressing both HPV18 E6 and E7. This indicates that expression of 
both the HPV oncoproteins is required to alter the morphology of Rat 1 cells. Future work 
should include introducing both HPV E6 and HPV E7 into an HPV -negative cell line to 
determine whether the expression of both oncoproteins are required to alter the cell 
morphology, growth rate and cell cycle profile of a previously HPV -negative cell. 
The discrepancy between our results and that in literature is unlikely to be due to passage 
number. The assays were carried out on cells 8 to 10 passages after transfection, which is 
similar to the study by Kinjo et ai. (2003), who reported effects 10 passages after 
transfection. The best method for investigating the effects at a higher passage number 
requires the use of single clones. The increase in the proportion of cells with DNA content 
greater than G2, seen 10 passages after transfection, in the slower-growing Ratl-ll E6 
pool, was not observed 20 passages after transfection (data not shown), implying the 
possibility that the faster growing cells in the pool out competed the slower growing cells 
(cells with a DNA content greater than 4N). 
4.1.2 Knocking out HPV E6 using peptide nucleic acids 
A second approach to investigating the role of HPV E6 genes was to knockout HPV E6 
expression in cells expressing the gene. There are several ways of knocking out genes 
such as the use of short interfering RNA or PNA. Peptide nucleic acids designed to target 
the HPV18 E6 gene (PNA1s) were used in this study. In addition, a mutant PNA (PNAmuD 
was also designed to control for non-specific effects and toxicity to cells. Previous work 
by Braun et ai. (2004) demonstrated that treating HeLa-S suspension cells with 3 PNAs, 











proliferation and an increase in apoptosis. The PNA-treated HeLa-S cells also had altered 
cell morphology and lost the ability to grow non-adherently. This current study sought to 
design and test a single PNA that targeted the HPV 18 E6 gene to determine whether a 
single PNA could be effective in decreasing HPV 18 E6 expression. Previous studies 
(Cutrona et al., 2000; 2003; Boffa et aI., 2007; Wang et al., 2004) have shown that the 
addition of a single PNA can be effective in decreasing the expression of its target gene. 
Since none of the eight OSCC cell lines that are routinely used in our laboratory tested 
positive for HPV L 1 or E6 DNA, HeLa cells were chosen as the model system for the PNA 
studies as they are known to contain HPV18 DNA and to produce the HPV E6 protein. 
The PNA18 used in this study decreased HPV18 E6 mRNA levels, indicating that the PNA 
interacted with the HPV 18 E6 gene and decreased transcription of the gene. The observed 
decrease was small (i.e. 15% and 35% after 24 and 48 hours of treatment, respectively) and 
this may be due to many different factors, including the design of the PNA and the poor 
uptake of the PNA into the nucleus of the cells. The design of the PNA is critical for their 
effectiveness. It has been observed that the closer the PNAs bind to the 5' end of the 
coding region of the gene, the more effective they are (Personal communication, Prof Lidia 
Boffa, 1ST, Genoa, Italy). PNA I8 was designed to bind at the 75
th base in the HPV18 E6 
exon, which is a distance from the start of the exon. 
Cutrona et al. (2000) showed that the addition of the nuclear localisation signal (NLS) 
(VKRKKKP) to the N terminus of the PNA was effective for uptake into the nucleus of 
Burkitt's lymphoma cells. However, a study (Bendifallah et al., 2006) using HeLa cells, 
tested the addition of the same NLS to PNA and showed that there was almost no activity 
of the PNA at a concentration of 10 /lM (same as the concentration used in this study and 
by Cutrona et al., 2000). Therefore, perhaps the NLS is effective for uptake in some cell 
lines, but not in others such as HeLa, but this needs to be confirmed in different cell lines. 
A study performed in HeLa cells (Wolf et al., 2006), showed that the best cell-penetrating 
peptide (CPP) to add to PNA to aid uptake was the KLA fragment (KLAL KLAL KAL 
KAAL KLA - NH2) added onto the N terminus of the PNA. They observed that a positive 
charge, helicity and amphipathicity were required to aid uptake. In contrast, in this project 











http://www.embl-heidelberg.de/services/serrano/agadir) and is not amphipathic. Many 
other CPP have been tested, for example Transportan and oligo-arginine (R7-9), to 
determine which is most effective (Morris et aI., 2007; Bendifallah et ai., 2006; Wolf et 
ai. , 2006). 
In this study the PNAmut caused a larger decrease in HPV18 E6 mRNA levels than PNA 18. 
This was an unexpected result as the PNAmut should not bind to the HPV18 E6 gene. 
However, after using the BLASTn programme to search in the NCBI database, it revealed 
that both the PNAmut and the PNA 18 were homologous to many human genes, some with 
100% homology. Furthermore the PNAmut also caused a decrease in the growth rate of 
HeLa cells. To determine whether the decrease in growth rate was HPV18 E6 specific, the 
HPV-negative cell line, WHC01, was treated with the PNA18 and PNAmut and a cell 
proliferation assay was performed. Treatment with either PNA18 or PNAmut resulted in a 
decrease in the growth rate ofWHC01 cells indicating that the observed decrease is due to 
cytotoxic effects of the PNAs. Furthermore, dead cells were observed 48 hours after 
treatment with either of the PNAs. 
All PNA experiments were performed using a final concentration of 10 )lM which was the 
concentration used by Cutrona et al. (2000). Some studies have shown that PNA are 
cytotoxic at higher concentrations, such as 10 j.LM. For example, the study by Wolf et al. 
(2006) showed that treatment with PNA at a final concentration of 4 )lM caused 80% cell 
death (assessed by MTT assay). Future experiments using PNA should optimise the cell-
specific concentration used to obtain a specific decrease in growth rate and decrease 
cytotoxic effects. 
To improve the effectiveness of the PNAs, the following recommendations are made; 
1) addition of a different cell penetrating peptide onto the PN A to increase cell uptake, 
2) designing of the PNA to bind closer to the 5' end ofthe gene, 












Oesophageal cancer is a multifactorial disease with variability in its geographical and 
gender distribution. While this study concentrated on HPV, the role of other risk factors 
such as genetic polymorphisms in xenobiotic metabolising enzymes, alcohol consumption 
and tobacco smoking is also important. From our observations, it appears that HPVl1 and 
HPV 18 E6 affect cells differently, however more work is required to determine whether 
HPVl1 E6 plays a role in the development of osee. Studies introducing the HPVll E6 
gene into embryonic oesophageal cell lines, similar to the studies by Shen et al. (2000; 
2001; 2003; 2004), and looking at the resultant effects over time may be able to answer 
some of the questions better than the systems used in this study. 
It is also necessary to look at the effects of HPV E7 on the oesophageal cells as perhaps 
both HPV E6 and E7 expression are required to transform the cells. In addition, the 
correlation between HPV E6 and exposure to carcinogens in the diet and the environment 
may be required in conjunction with HPV E6 expression to transform the cells. Suitable 
PNAs targeting HPV 18 E6 may be a possible treatment option for HPV -positive cancers. 
It has been shown that continuous HPV E6 expression is required in cervical cancer cells 
to maintain the transformed phenotype (Homer et aI., 2004) therefore, in decreasing 
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Figure A.I: DNA Molecular Weight Markers. a) GeneRuler 50 bp DNA Ladder 
(Fennentas, Maryland, USA) b) 1 Kb Plus Marker (Invitrogen, Paisley, UK). c) Marker 
VIII (Roche, Mannheim, Gennany), mixture ofpUCBM21 DNA cleaved with Hpal1, and 
pUCBM21 DNA cleaved with Dral and HindI II. d) Marker X (Roche, Mannheim, 
Gennany), mixture containing a 1018 bp fragment derived from the 2 ).l plasmid of the 
yeast Saccharomyces cerevisiae, multimers of this fragment, and cleavage products from 
pBR322 DNA. These markers were used to estimate the size of DNA fragments 

















Fi2:ure A.2: PRN800 Molecular Weight Marker (Amersham Biosciences, 
Buckinghamshire, England), This protein molecular weight marker was used to estimate 
the size of proteins electrophoresed on denaturing polyacrylamide gels. 
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Figure A.3: pcDNA3.1 plus expression vector (Invitrogen, Paisley, UK). The HPVll E6 















10 mM Tris-CI, pH 8.0 
25 mM EDT A, pH 8.0 
0.5% SDS 
0.1 mg/ml proteinase K 
Fixing solution 
25% (v/v) isopropanol 
10% (v/v) acetic acid 
APPENDIXB 
Formaldehyde-containing agarose gel 
1.5% agarose in MOPS buffer 
0.5 ~g1~1 ethidium bromide 
2% formaldehyde 
Laemmli buffer 
62.5 mM Tris, pH 6.8 
1.5% SDS 
0.00125% bromophenol blue 
10% glycerol 
2.5% ~-mercaptoethanol 
Luria broth (LB) 
1 Ogll tryptone powder 
5gll yeast extract powder 
85.5 mMNaCI 
Luria Agar 
LB containing 14 gil agar 
MOPS Buffer 
0.02 mM MOPS, pH 5.5-7.0 
5 mM Sodium acetate 
1 mM EDTA 
Mowiol mounting solution 
2.4 g Mowiol® 4-88 Reagent 
6ml glycerol 
Leave at room temperature for at least 4 hours 
Add 12 ml 0.2 M Tris (PH 8.5) 
Incubate at 50°C for 1 hour with occasional stirring 











4% Paraformaldehyde (PFA) in PBS 
2.5 ml 16% PF A dissolved in water 
1 ml lOX PBS 
6.5 ml distilled water 
Store at -20°C 
25:24:1 (v/v/v) Phenol:Chloroform:lsoamyl alcohol 
50 ml phenol 
48ml chloroform 
2 ml isoamyl alcohol 
Store at 4°C 
Phosphate-buffered saline (PBS) 
137 mM NaCl 
2.7 mMKCl 
4.3 mM Na2HP04 
1.4 mM KH2P04 
pH to 7.5 
Ponceau S stain 
1 gil Ponceau S 
10% glacial acetic acid 
Propidium iodide stain solution 
0.1 % Triton X-I 00 
2mMMgCh 
100 mM NaCl 
10 mM PIPES, pH 6.8 
10 Ilg/ml propidium iodide 
Rapid Coommasie blue 
10% acetic acid 
0.006% (w/v) Coomassie brilliant blue 




0.04% bromophenol blue in MOPS 
RIPA buffer 
150 mM NaCl 
10 mM Tris, pH 7.2 
0.1% SDS 
1 % Triton X-I 00 
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